WO2014185549A1 - 細胞のエピジェネティックな情報を得る方法、細胞の特性を判定する方法、薬剤感受性を判断するまたは薬剤若しくは免疫療法剤の種類を選択する方法、疾患の診断方法、並びに自己複製ベクター、アッセイキットおよび分析装置 - Google Patents

細胞のエピジェネティックな情報を得る方法、細胞の特性を判定する方法、薬剤感受性を判断するまたは薬剤若しくは免疫療法剤の種類を選択する方法、疾患の診断方法、並びに自己複製ベクター、アッセイキットおよび分析装置 Download PDF

Info

Publication number
WO2014185549A1
WO2014185549A1 PCT/JP2014/063214 JP2014063214W WO2014185549A1 WO 2014185549 A1 WO2014185549 A1 WO 2014185549A1 JP 2014063214 W JP2014063214 W JP 2014063214W WO 2014185549 A1 WO2014185549 A1 WO 2014185549A1
Authority
WO
WIPO (PCT)
Prior art keywords
sequence
nucleic acid
self
reporter
protein
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/JP2014/063214
Other languages
English (en)
French (fr)
Japanese (ja)
Inventor
斉湖 吉村
美津子 石原
英一 赤星
康雄 櫻井
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Toshiba Corp
Canon Medical Systems Corp
Original Assignee
Toshiba Corp
Toshiba Medical Systems Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Toshiba Corp, Toshiba Medical Systems Corp filed Critical Toshiba Corp
Priority to CN201480028611.5A priority Critical patent/CN105308188B/zh
Priority to EP14797267.3A priority patent/EP2998408B1/en
Priority to JP2015517155A priority patent/JP6140277B2/ja
Publication of WO2014185549A1 publication Critical patent/WO2014185549A1/ja
Priority to US14/943,766 priority patent/US20160153057A1/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6897—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids involving reporter genes operably linked to promoters

Definitions

  • Embodiments of the present invention include methods for obtaining epigenetic information on cells, methods for determining cell characteristics, methods for determining drug sensitivity or selecting the type of drug or immunotherapeutic agent, methods for diagnosing disease, and self
  • the present invention relates to a replication vector, an assay kit, and an analysis apparatus.
  • Factors involved in gene expression include those involving changes in the base sequence of DNA constituting the genome and those not involving changes in the DNA base sequence. Those accompanied by changes in the base sequence of DNA include polymorphisms or mutations. On the other hand, those not accompanied by changes in DNA base sequence include changes related to epigenetic control. Such polymorphisms and mutations, and information on epigenetic control (ie, epigenetic information) are useful in various fields such as medicine, agriculture, and fishery. Epigenetic information includes DNA modification, histone chemical modification, and control by non-translatable RNA.
  • epigenetic information such as the presence or absence of modification such as methylation for a specific base sequence and the change in modification amount.
  • DNA methylation abnormality has been confirmed from an early stage in a multi-stage carcinogenic process.
  • methylation in the target gene cluster has been confirmed in early liver cancer.
  • the methylation reaction of genomic DNA means that a methyl group is added to cytosine on the genome by DNA methyltransferase in the cell.
  • the replicated genome undergoes addition of a methyl group to cytosine at the same position as the genome before replication.
  • means for detecting DNA methylation include, for example, a bisulfate-treated PCR method, a sequencing method, and a method using a reporter vector.
  • a method using a reporter vector a method of screening a circadian rhythm disorder improving agent by assaying a circadian rhythm control mechanism by DNA methylation of a clock gene has been reported.
  • a stable expression cell line in which a known target nucleic acid sequence that is methylated in a cell is incorporated on a chromosome is prepared, and a methylation reaction that is performed simultaneously with genome replication during cell division is used to perform an outline. This is a method for screening a daily rhythm disorder improving agent.
  • Embodiment aims at providing the method of obtaining the epigenetic information of a cell simply.
  • a method for obtaining epigenetic information of a cell is provided. This method was obtained by introducing a reporter nucleic acid construct into the nucleus of a test cell, allowing the reporter nucleic acid construct to self-replicate, detecting the presence and / or magnitude of a signal generated in the test cell, Obtaining epigenetic information of the test cell based on the result.
  • Reporter nucleic acid constructs copy the state of modification in a particular sequence on the genome of the test cell onto the corresponding sequence by substitution of functional groups during self-replication in the nucleus of the test cell. It generates a detectable signal depending on the presence of the functional group.
  • FIG. 1 is a diagram showing an example of a self-replicating vector.
  • FIG. 2 is a diagram showing an example of a self-replicating vector.
  • FIG. 3 is a diagram showing an example of a self-replicating vector.
  • FIG. 4 is a diagram showing an example of a self-replicating vector.
  • FIG. 5 is a diagram showing an example of a self-replicating vector.
  • FIG. 6 is a diagram showing an example of a self-replicating vector.
  • FIG. 7 is a diagram showing an example of a self-replicating vector.
  • FIG. 8 is a scheme showing an example of a method for obtaining epigenetic information of cells.
  • FIG. 9 is a scheme showing an example of a method for obtaining epigenetic information of cells.
  • FIG. 9 is a scheme showing an example of a method for obtaining epigenetic information of cells.
  • FIG. 10 is a scheme showing an example of a method for obtaining epigenetic information of cells.
  • FIG. 11 is a scheme showing an example of a method for obtaining epigenetic information of cells.
  • FIG. 12 is a diagram illustrating an example of a method for determining characteristics of a test cell.
  • FIG. 13 is a block diagram showing an analyzer for performing a method for obtaining epigenetic information of cells.
  • FIG. 14 is a diagram showing an example of a process for producing a self-replicating vector containing a methylated target sequence.
  • FIG. 15 is a graph showing experimental results.
  • FIG. 16 is a diagram showing a CK19 promoter region and a self-replicating vector containing a replication initiation sequence.
  • FIG. 17 is a diagram showing a replication initiation protein gene expression vector.
  • FIG. 18 shows the position of the CCGG sequence in the CK19 promoter region.
  • FIG. 19 is a diagram showing experimental results.
  • FIG. 20 is a diagram showing experimental results.
  • FIG. 21 is a diagram showing experimental results.
  • FIG. 22 is a diagram showing experimental results.
  • FIG. 23 is a diagram of a self-replicating vector containing a COX2 promoter region and a replication initiation sequence.
  • FIG. 24 shows the position of the CCGG sequence in the COX2 promoter region.
  • FIG. 25 is a diagram showing experimental results.
  • FIG. 26 is a diagram showing experimental results.
  • FIG. 27 is a diagram showing experimental results.
  • FIG. 28 is a diagram showing experimental results.
  • FIG. 29 is a diagram showing experimental results.
  • FIG. 30 is a diagram showing experimental results.
  • FIG. 31 is a diagram showing experimental results.
  • FIG. 32 shows the results of luciferase assay.
  • FIG. 33 is a diagram showing an example of a method for producing a self-replicating vector containing a methylated target sequence.
  • FIG. 34 is a schematic diagram showing co-transfection of two types of vectors into cells.
  • FIG. 35 is a diagram showing an example of a self-replicating vector.
  • FIG. 36 is a diagram showing experimental results.
  • the method for obtaining epigenetic information of cells uses a self-replicating reporter nucleic acid construct.
  • this reporter nucleic acid construct self-replicates in the nucleus of a test cell, the state of modification on a specific sequence in the genome of the test cell is copied to its own sequence. That is, the reporter nucleic acid construct contains a sequence that is homologous to the particular sequence to be observed.
  • the modification state on a specific sequence in the genome is copied (copied) to a sequence homologous to that in the reporter nucleic acid construct.
  • the reporter nucleic acid construct produces a detectable signal depending on the presence of the functional group copied to the reporter nucleic acid construct. At this time, the presence / absence, size, or amount of a signal varies depending on the presence of functional groups. Thereby, the reporter nucleic acid construct reports the modification status on a specific sequence of the genome.
  • the report function of the reporter nucleic acid construct can be obtained only when the reporter nucleic acid construct self-replicates.
  • the reporter nucleic acid construct is introduced into the nucleus of the test cell that is placed under conditions that initiate self-replication of the reporter nucleic acid construct.
  • a signal generated by the reporter nucleic acid construct is detected in the test cell.
  • the detection of the signal may be performed on the presence or absence of the signal, and may be performed on the magnitude or amount of the signal.
  • the result obtained by the detection is epigenetic information of the test cell.
  • cell epigenetic information means whether a functional group is bound to a base constituting a specific sequence on the genome of a test cell, whether there is a substitution, or not. It may be information about such as.
  • the “detectable signal” may be fluorescence, luminescence, color, or the like, or may be a presentation of a substance such as a protein. Alternatively, it may be a signal that can be detected by a method known per se, for example. In addition, the presence / absence or magnitude of the signal varies depending on the presence of the functional group copied to the reporter nucleic acid construct.
  • a “reporter nucleic acid construct” is a nucleic acid construct for reporting epigenetic information of cells to be tested. Examples of correlations between reporter nucleic acid constructs and modifications in specific sequences of the genome are described below. The following example is an example where the epigenetic information is information on methylation in a specific sequence of the genome. Table 1 shows the correlation between the reporter activity of the reporter nucleic acid construct and methylation.
  • the correlation shown in Table 1 is an example in which the signal of the reporter nucleic acid construct increases with demethylation of the corresponding sequence of the reporter nucleic acid construct and decreases with methylation.
  • This reporter nucleic acid construct can be used, for example, for detection of cancer. In the case of cancer cells, demethylation occurs at specific sequences on the genome.
  • Such epigenetic information in cells is copied to the corresponding sequence contained in the reporter nucleic acid construct during its self-replication. For example, if the corresponding sequence of the reporter nucleic acid construct is previously methylated, demethylation occurs during self-replication. At this time, the detectable signal from the reporter nucleic acid construct is increased. For example, cancer can be detected using such detection of a large signal as an index.
  • the “corresponding sequence” is a sequence homologous to a specific sequence on the genome, ie, the sequence where the modification to be detected is located.
  • a reporter nucleic acid construct containing many methyl groups is prepared (A-1). It is assumed that a specific sequence on the genome contains many methyl groups (A-2-1). In this case, there is little or no functional group substitution in the construct when self-replicating (A-3-1). In this case, the detection signal is small (A-4-1). The reporter activity is relatively low (A-5-1). On the other hand, it is assumed that a specific sequence on the genome does not contain many methyl groups (A-2-2). In this case, when self-replicating, the functional group is substituted in the construct and demethylation occurs (A-3-2). In this case, the detection signal is large (A-4-2). The reporter activity is relatively high (A-5-2).
  • a reporter nucleic acid construct containing a small number of methyl groups is prepared (B-1). It is assumed that a specific sequence on the genome contains many methyl groups (B-2-1). In this case, when self-replicating, the functional group in the construct is displaced and methylation occurs (B-3-2). In this case, the detection signal is small (B-4-2). In this case, the signal becomes smaller as time passes. The reporter activity is relatively low (B-5-2). On the other hand, a specific sequence on the genome does not contain many methyl groups (B-2-2). In this case, there is little or no functional group substitution in the construct when self-replicating (B-3-2). In this case, the detection signal is large (B-4-2). The reporter activity is relatively high (B-5-2).
  • the reporter nucleic acid construct may be, for example, a self-replicating vector.
  • a self-replicating vector as a reporter nucleic acid construct will be described below with reference to the drawings.
  • symbol is attached
  • the configurations of the embodiments may be combined and used in one embodiment, or a plurality of embodiments may be used simultaneously in one analysis.
  • a self-replicating vector is used under conditions where a replication initiator protein is expressed in the cell.
  • Self-replicating vectors are also referred to as “reporter vectors”.
  • the self-replicating vector 1 includes a reporter gene expression unit 2 and a replication initiation sequence 3.
  • the replication initiation sequence 3 is present on the same nucleic acid as the reporter gene expression unit 2.
  • the reporter gene expression unit 2 includes a target nucleic acid sequence 4, a reporter gene 5 encoding a reporter protein, and a transcription termination signal sequence 6.
  • the target nucleic acid sequence 4 is a nucleic acid sequence from which epigenetic information should be obtained.
  • the target nucleic acid sequence 4 has homology with the specific nucleic acid sequence of the test cell.
  • the target nucleic acid sequence 4 has a modified base.
  • the self-replicating vector 1 (for example, the target nucleic acid sequence 4) has a promoter activity that depends on the degree of modification at the base to be modified. Activation of the promoter activity of the self-replicating vector 1 (for example, the target nucleic acid sequence 4) is controlled by modification of the modified base on the target nucleic acid sequence 4.
  • Such modified bases are targets for modification.
  • the target nucleic acid sequence 4 may be selected in advance as desired. From the epigenetic information obtained with respect to the target nucleic acid sequence 4, epigenetic information of a specific nucleic acid sequence in the test cell can be obtained.
  • sequence having homology with respect to the target nucleic acid sequence 4 may be the same sequence as a specific sequence on the genome or a sequence substantially the same as the specific sequence on the genome.
  • a sequence substantially identical to a specific sequence on the genome refers to, for example, a sequence in which one or several bases are substituted, deleted or added in the specific sequence.
  • the “specific sequence” may be a sequence from which epigenetic information is to be obtained. For example, “having homology”, “homologous”, and “homologous” may be sequences that are 90% or more or 95% or more identical to the genome sequence.
  • sequence which consists of may be sufficient.
  • the target nucleic acid sequence 4 may be a sequence obtained by integrating homologous sequences with two or more sequences present at a plurality of positions on the genome, or may include such an integrated sequence. Good. In other words, assuming that each of two or more sequences present at a plurality of positions on the genome is one unit, the target nucleic acid sequence 4 is a sequence in which homologous sequences are integrated with each of the plurality of units. Or may comprise such an integrated arrangement. In other words, the target nucleic acid sequence 4 may be composed of two or more units corresponding to units that are homologous sequences on the genome.
  • one unit is homologous to a part of a specific promoter sequence on the genome, and the other unit has a modified base capable of controlling the activation of the promoter sequence. It may be homologous to the containing sequence.
  • a part of a specific promoter sequence on the genome and a sequence containing a modified base capable of controlling the activation of this promoter sequence do not necessarily exist continuously on the genome. That is, further sequences may be included between them. If such additional sequences are sequences that do not affect the promoter sequence and its activity, such additional sequences need not necessarily be included in the target nucleic acid sequence 4. Moreover, as long as it has a promoter activity that depends on the modified base on the target nucleic acid sequence 4 and the degree of modification of the modified base, the target nucleic acid sequence 4 is a sequence having homology with the sequence on the genome of the test cell. In addition, any further sequences may be included.
  • any additional sequence does not prevent having a promoter activity that depends on the modified base on the target nucleic acid sequence 4 and the degree of modification at the modified base.
  • any further sequence may be included between any bases that make up a sequence having homology to the sequence on the genome of the test cell, and is homologous to the sequence on the genome of the test cell. May be included adjacent to a sequence having
  • sequence having homology with respect to the sequence on the genome is described with respect to the target nucleic acid sequence 4, but “sequence with homology” with respect to the target nucleic acid sequence 4 is also described with respect to the test cell. It should be understood similarly.
  • the self-replicating vector 1 is a vector that replicates itself after being introduced into a test cell.
  • the target nucleic acid sequence 4 is a sequence having homology with a specific nucleic acid sequence contained in the genome of the test cell. With such a configuration, it is possible to copy the modification state of the homologous sequence on the genome of the test cell to the target nucleic acid sequence 4 in the self-replicating vector 1 using the self-replicating ability of the self-replicating vector 1. Become.
  • target nucleic acid sequence 4 examples include, but are not limited to, a SOX2 gene promoter sequence, a GFAP gene promoter sequence, a CK19 gene promoter sequence, and a COX2 gene promoter sequence.
  • the modification of the target nucleic acid sequence 4 is, for example, methylation or alkylation.
  • the state of modification of the target nucleic acid sequence 4 means whether a methyl group and / or an alkyl group, which is a functional group, is bonded or not bonded to the base constituting the target nucleic acid sequence 4. It is.
  • the “epigenetic information” of the test cell may be whether such a functional group exists or not. Alternatively, it may be information on how much functional group is present. Alternatively, it may be information such as a change in the state of such modification, ie, the presence or absence or degree of functional group substitution. Further, any combination thereof may be used.
  • the modification of the target nucleic acid sequence 4 may be a modification to cytosine and / or guanine in the main chain of the target nucleic acid sequence 4, for example.
  • the modification may be related to one or more of them.
  • the modification of the target nucleic acid sequence 4 may be methylation on cytosine and / or guanine in the target nucleic acid sequence 4.
  • Promoter activity means inducing transcription of a gene operably linked downstream of the promoter sequence.
  • the promoter activity may be derived from the entire sequence of the target nucleic acid sequence 4 or may be derived from a partial sequence of the target nucleic acid sequence 4.
  • the target nucleic acid sequence 4 may include a minimal promoter.
  • the modified base may be present continuously or intermittently throughout the entire sequence capable of exhibiting the promoter activity of the target nucleic acid sequence 4, and the modified base is included in the sequence of the target nucleic acid sequence 4 other than the sequence capable of exhibiting the promoter activity. May be present or a combination thereof.
  • Promoter activation of the target nucleic acid sequence 4 is controlled by the modification state of the base to be modified on the target nucleic acid sequence 4.
  • the promoter activity of the target nucleic acid sequence 4 is activated depending on the degree of base modification in the sequence of the target nucleic acid sequence 4.
  • the promoter activity of the target nucleic acid sequence 4 is activated, for example, when the degree of modification at the modified base of the target nucleic acid sequence 4 is low, or activated when there is a modification, or when there is no modification Any of these may be used.
  • the nature of the target nucleic acid sequence 4 with respect to such promoter activity is “activated depending on the degree of base modification in the target nucleic acid sequence 4” or “depending on the degree of functional group substitution at the base. Is activated ”.
  • An example of a sequence having a promoter activity depending on the degree of modification of the base to be modified in the sequence of the target nucleic acid sequence 4 may be, for example, a sequence derived from a test cell, or may be a sequence synthesized artificially.
  • an example of such a sequence may be the 5 ′ upstream region ( ⁇ 1651 to +32 bp) (SEQ ID NO: 1) of a glial fibrillary acidic protein (GFAP) gene.
  • SEQ ID NO: 1 of a glial fibrillary acidic protein (GFAP) gene.
  • the 5 ′ upstream region sequence of the GFAP gene is activated when there is no methylation of the target nucleic acid sequence.
  • Table 2 The sequence is shown in Table 2.
  • a reporter gene 5 is operably linked downstream of the target nucleic acid sequence 4. That is, the target nucleic acid sequence 4 is operably linked upstream of the reporter gene 5.
  • the reporter gene 5 is transcribed when the target nucleic acid sequence 4 is activated. This transcription causes the reporter protein to be expressed.
  • the reporter protein may be detected by detecting fluorescence, luminescence, color, or the like, or may be detected by a known protein detection means.
  • the reporter protein may be, for example, luciferase, ⁇ -galactosidase, nitric oxide synthase, xanthine oxidase, blue fluorescent protein, green fluorescent protein, red fluorescent protein, and heavy metal binding protein.
  • the reporter gene 5 may be a gene encoding these proteins. Examples of the reporter gene 5 include a luciferase gene, ⁇ -galactosidase gene, nitric oxide synthase gene, xanthine oxidase gene, blue fluorescent protein gene, green fluorescent protein gene, red fluorescent protein gene, and heavy metal binding protein gene.
  • the transcription termination signal sequence 6 may be any sequence that terminates the transcription of the upstream gene, and may be, for example, a poly (A) addition signal.
  • the poly (A) addition signal may be any signal that functions to terminate transcription of mammalian genes. Examples include the late poly (A) addition signal (SEQ ID NO: 4) of the SV40 virus and the poly (A) addition signal (SEQ ID NO: 5) of the bovine growth hormone gene.
  • the poly (A) addition signal that can be used in the practice of this embodiment is not limited to this, and the modified poly (A) addition signal may be used as long as the function as the poly (A) addition signal is not impaired. It may be used.
  • the sequences of these poly (A) addition signals are shown in Table 5.
  • “Functional” with respect to the linking of a plurality of sequences means a state in which each gene is linked in a state where it can exert its intended function.
  • a sequence encoding a protein it means that the amino acid sequences encoded by the respective base sequences are correctly linked. In other words, it means that there is no shift in the frame of the amino acid codon and a peptide that functions in the target activity is synthesized in the cell into which the base sequence is introduced.
  • the term “functionally coupled” may be used interchangeably with the term “operably coupled”.
  • the transcription termination signal sequence 6 is operably linked downstream of the reporter gene 5.
  • the self-replicating vector 1 can self-replicate in the test cell under the condition that the replication initiation protein is expressed in the test cell.
  • the replication initiation sequence 3 is a sequence that initiates self-replication upon binding of a replication initiation protein.
  • the replication initiation sequence 3 may be a sequence that is activated by binding of a replication initiation protein and initiates self-replication in mammalian cells, for example, and may be a replication initiation sequence known per se.
  • the replication initiation sequence 3 may be, for example, a replication initiation sequence derived from simian virus 40 (SEQ ID NO: 6), Epstein-Barr virus, or mouse polyoma virus, but is not limited thereto. Table 6 shows an example of the replication start sequence.
  • the self-replicating vector 1 may be any vector capable of self-replication, for example, a plasmid vector.
  • a plasmid vector known per se may be used.
  • an example of a plasmid vector of this self-replicating vector is disclosed in JP2013-42721.
  • Self-replication of the self-replicating vector 1 is initiated by binding of a replication initiator protein to the replication initiator sequence 3.
  • FIG. 2 schematically shows a state in which the replication initiator protein 7 binds to the replication initiator sequence 3 of the self-replicating vector 1.
  • the replication initiating protein 7 binds to the replication initiating sequence 3, and a plurality of proteins involved in DNA replication further bind.
  • the self-replicating vector 1 is replicated in the test cell by the plurality of bound proteins.
  • the replication initiator protein 7 is expressed under “conditions for the replication initiator protein to be expressed in the cell”.
  • the “conditions for expressing the replication initiator protein in the cell” may be any conditions as long as the replication initiator protein that initiates self-replication of the self-replicating vector 1 is expressed in the cell into which the vector is introduced. That is, it suffices if the replication initiation protein unit exists in the test cell into which the self-replicating vector 1 is to be introduced.
  • the “replication initiation protein unit” is a unit for expressing a replication initiation protein, and may also be referred to as a “replication initiation protein expression unit”.
  • the replication initiating protein unit may include a sequence capable of expressing a replication initiating protein that causes the self-replicating vector 1 to initiate self-replication.
  • the replication initiating protein unit may consist of a sequence capable of expressing a replication initiating protein that causes the self-replicating vector 1 to initiate self-replication.
  • the replication initiator protein unit is operably linked downstream from a promoter that controls the expression of a sequence that encodes the replication initiator protein, and a sequence that encodes a replication initiator protein operably linked downstream thereof.
  • a transcription termination signal sequence is operably linked downstream from a promoter that controls the expression of a sequence that encodes the replication initiator protein, and a sequence that encodes a replication initiator protein operably linked downstream thereof.
  • a replication initiator protein unit is operably linked downstream from a promoter that controls the expression of a sequence that encodes the replication initiator protein, and a sequence that encodes a replication initiator protein operably linked downstream thereof. And a transcription termination signal sequence.
  • sequences encoding a replication initiator protein that binds to the replication initiator sequence 3 and causes the self-replicating vector 1 to initiate self-replication are as follows. That is, it may be, for example, the simian virus 40 large T antigen gene, the Epstein Barr virus EBNA-1 gene, the mouse polyoma virus large T antigen gene, and the like.
  • Examples of preferred large T antigen genes are shown in Table 7, Table 8 and Table 9, respectively. That is, it may be a nucleic acid shown in SEQ ID NO: 7, SEQ ID NO: 8 or SEQ ID NO: 9, respectively. Alternatively, it may be a nucleic acid represented by a sequence in which one or several bases in the sequence of SEQ ID NO: 7, SEQ ID NO: 8 or SEQ ID NO: 9 are deleted, substituted or added, and having a DNA replication initiation function.
  • the DNA replication initiation function refers to encoding a protein capable of initiating replication.
  • the replication initiating protein unit may be present on the nucleic acid of the self-replicating vector 1 or may be present on a nucleic acid different from the nucleic acid of the self-replicating vector 1.
  • the replication initiator protein unit may be present on the chromosome of the test cell or may be present on another nucleic acid contained in the test cell. May be.
  • the replication initiating protein unit has the following configuration. That is, it comprises or comprises a constitutively expressed promoter, a sequence encoding a replication initiator protein operably linked downstream thereof, and a transcription termination signal sequence operably linked downstream thereof. Consisting of an array of With such a configuration, the sequence that encodes the replication initiator protein may be transcribed and translated to produce the replication initiator protein.
  • the replication initiating sequence 3 may be included in the self-replicating vector 1.
  • the expression of the reporter gene expression unit 2 and the replication initiation protein unit in the self-replicating vector 1 may be controlled by one promoter, or may be controlled by two independent or the same different promoters.
  • the replication initiator protein unit is present on the nucleic acid of the self-replicating vector 1 independently of the reporter gene expression unit 2.
  • the replication initiator protein unit may comprise a constitutively expressed promoter and a sequence encoding the replication initiator protein operably linked downstream thereof.
  • a transcription termination signal sequence may be operably linked downstream of the sequence encoding the replication initiator protein.
  • the structure when the reporter gene expression unit 2 and the replication initiating protein unit are expressed by being controlled by one promoter, for example, the structure may be as follows.
  • An example of such a self-replicating vector 1 is, for example, an IRES (internal ribosomal entry site) sequence (SEQ ID NO: 10) operatively linked downstream of a reporter gene expression unit and a functionally linked downstream of an IRES sequence. And a transcription termination signal sequence operatively linked downstream thereof.
  • the sequence of the IRES sequence is shown in Table 10.
  • Such a replication initiator protein unit encodes a sequence encoding a replication initiator protein, a constitutively expressed promoter operably linked upstream thereof, and a replication initiator protein operably linked downstream thereof. It comprises or consists of a sequence and a transcription termination signal sequence operably linked downstream thereof.
  • the sequence encoding the replication initiator protein is transcribed and translated to produce the replication initiator protein.
  • the self-replicating vector 1 includes a replication initiation sequence in the same vector.
  • the produced replication initiator protein binds to the replication initiator sequence in the vector.
  • Such a self-replicating vector will be described in the second embodiment as an example of a plasmid vector.
  • the replication initiating protein unit When the replication initiating protein unit is present on the genome of the test cell, for example, the replication initiating protein is generated as follows.
  • the replication initiator protein gene expression vector is introduced into a test cell using a transfection method or a viral vector, and cultured, whereby the replication initiator protein gene expression vector is integrated into the cell chromosome.
  • the transfection method may be performed by a biochemical method or a physicochemical method.
  • Biochemical methods include lipofection methods using cationic lipids, magnetofection methods using magnetic particles, and methods using calcium chloride. Examples of the physicochemical method include electroporation.
  • the biochemical methods and physicochemical methods described above may be used alone or in combination with each other.
  • the lipofection method that is a biochemical method and the magnetofection method may be used in combination, or the lipofection method that is a biochemical method and the electroporation method that is a physicochemical method are combined. It may be used.
  • ⁇ Replication initiation protein gene expression vector is stably integrated into the chromosome, so that the replication initiation protein gene is stably transcribed and translated in the test cell to produce the replication initiation protein.
  • Examples of cell lines that stably express the replication initiation protein include HEK293T cells and COS cells.
  • the replication initiating protein unit When the replication initiating protein unit is present on a different nucleic acid chain from the nucleic acid of the self-replicating vector 1 and the chromosome of the test cell, the replication initiating protein unit is contained in a second vector other than the self-replicating vector 1. May exist.
  • a second vector may be a vector that expresses a replication initiator protein in a test cell, and any vector known per se may be used.
  • Such a second vector is also referred to as a “replication initiation protein gene expression vector”.
  • the replication initiator protein unit may be included in a self-replicating vector.
  • the test cell may contain a self-replicating vector and a further sequence different from the genome of the test cell, and such a further sequence may contain a replication initiator protein unit.
  • additional sequences may be included in the chromosome of the test cell or in additional nucleic acid strands such as a second vector.
  • the combination of the gene encoding the replication initiation protein and the replication initiation sequence may be a combination that can initiate replication. Examples of such combinations are: A combination in which the gene encoding the replication initiator protein is a large T antigen gene of simian virus 40 and the replication initiator sequence is a replication initiator sequence from simian virus 40; A combination in which the gene encoding the replication initiator protein is the Epstein-Barr virus EBNA-1 gene, and the replication initiator sequence is the replication initiator sequence from Epstein-Barr virus; A combination in which the gene encoding the replication initiator protein is a large T antigen gene of mouse polyomavirus and the replication initiator sequence is a replication initiator sequence from mouse polyomavirus. Combinations such as these are preferred, but are not limited thereto.
  • the test cell may be, for example, a cell group and / or a single cell.
  • the test cells may be cells contained in blood, urine, feces, semen, saliva, biopsy tissue, oral mucosa, body cavity fluid, sputum, etc., or may be cultured cells. .
  • Introduction of the self-replicating vector 1 into a test cell may be performed in vitro or in vivo.
  • a self-replicating vector 31 that is a plasmid vector includes a target nucleic acid sequence 4, a reporter gene 5 operably linked downstream thereof, an IRES 32 operably linked downstream thereof, and downstream thereof.
  • a sequence 33 encoding a replication initiator protein operably linked to a transcription termination signal sequence 34 functionally linked downstream thereof, and a replication initiation sequence 3 operably linked downstream thereof.
  • the components of the reporter gene expression unit 2 are a target nucleic acid sequence 4, a reporter gene 5, and a transcription termination signal sequence 34.
  • the components of the replication initiator protein unit are the target nucleic acid sequence 4, IRES 32, a sequence 33 encoding the replication initiator protein, and a transcription termination signal sequence 34.
  • IRES is an abbreviation for “internal ribosomal entry site” and is referred to as “internal ribosome binding sequence”.
  • the IRES may be, for example, a sequence derived from encephalomyocarditis virus. Due to the presence of IRES32, the sequence of the reporter gene 5 is transcribed by the target nucleic acid sequence 4 activated depending on the degree of modification of the base in the sequence of the target nucleic acid sequence 4 and subsequently encodes the replication initiator protein. Sequence 33 is transcribed. After the sequence 33 encoding the replication initiation protein is read, the transcription is terminated by the presence of the transcription termination signal sequence 34. The replication initiator protein produced by being transcribed and translated from the sequence 33 encoding the replication initiator protein is bound to the replication initiator sequence 3, and the replication of the self-replicating vector 31 is started.
  • the modified base of the target nucleic acid sequence 4 may or may not be modified at the time of vector introduction.
  • the modified base of the target nucleic acid sequence 4 contained in such a self-replicating vector 31 behaves as follows after being introduced into the test cell. First, when the modification state of the target nucleic acid present in the test cell is high, the modified base of the target nucleic acid sequence 4 is highly modified, so that the target nucleic acid sequence 4 is not activated and the reporter gene And the replication initiation protein gene is not expressed. Accordingly, the self-replication of the self-replicating vector 31 is stopped. On the other hand, when the modification state of the target nucleic acid present in the test cell is low or unmodified, the modification state of the base to be modified of the target nucleic acid sequence 4 is maintained low. Sequence 4 is activated.
  • the reporter gene 5 linked by the IRES 32 and the sequence 33 encoding the replication initiator protein are transcribed and translated into bicistronic mRNA.
  • the two genes are transcribed as a single bicistronic mRNA.
  • the ribosome not only translates the reporter gene 5 from the bicistronic mRNA, but also binds to the position of the IRES and translates the sequence encoding the replication initiator protein.
  • the transcription termination signal sequence 34 is a base sequence that encodes a signal for terminating transcription between the reporter gene 5 and the sequence 33 that encodes the replication initiation protein.
  • the replication initiator protein transcribed from the sequence 33 encoding the replication initiator protein and translated by the components of the test cell recognizes the replication initiator sequence 3 and binds thereto. Further, a plurality of proteins related to DNA replication contained in the test cell are bound.
  • the self-replicating vector 31 is self-replicated in the test cell by the plurality of bound proteins.
  • the modified base of the target nucleic acid sequence 4 When the modified base of the target nucleic acid sequence 4 is modified, it behaves as follows after being introduced into the test cell. First, when the modification state of the target nucleic acid present in the test cell is high, the target nucleic acid sequence 4 is not activated because the original modification degree is maintained at the base to be modified of the target nucleic acid sequence 4. . Therefore, the reporter gene and the replication initiation protein gene are not expressed. Accordingly, the self-replication of the self-replicating vector 31 is stopped. On the other hand, when the modification state of the target nucleic acid present in the test cell is low or unmodified, the modification state of the modification base in the modification base of the target nucleic acid sequence 4 is reduced or eliminated, so Is activated.
  • the reporter gene 5 linked by the IRES 32 and the sequence 33 encoding the replication initiator protein are transcribed and translated into bicistronic mRNA.
  • the two genes are transcribed as a single bicistronic mRNA.
  • the ribosome not only translates the reporter gene 5 from the bicistronic mRNA, but also binds to the position of the IRES and translates the sequence encoding the replication initiator protein.
  • the transcription termination signal sequence 34 is a base sequence encoding a signal for terminating the transcription of the reporter gene 5 and the sequence 33 encoding the replication initiation protein.
  • the replication initiator protein transcribed from the sequence 33 encoding the replication initiator protein and translated by the components of the test cell recognizes the replication initiator sequence 3 and binds thereto. Further, a plurality of proteins related to DNA replication contained in the test cell are bound.
  • the self-replicating vector 31 is self-replicated in the test cell by the plurality of bound proteins.
  • the reporter gene 5 is expressed when the degree of modification at the base to be modified of the target nucleic acid sequence 4 is low. Furthermore, self-replication of the self-replicating vector 31 is started by reading a sequence existing downstream thereof. The replication product generated by the self-replication of the self-replicating vector 31 has the same sequence as the self-replicating vector 31 with respect to the sequence. However, the modification state of the target nucleic acid present in the test cell is reflected in the modification state of the modified base of the target nucleic acid sequence 4. As a result, when the degree of modification at the base to be modified of the target nucleic acid sequence 4 increases, the target nucleic acid sequence 4 is not activated. Therefore, the reporter gene 5 is not expressed, and further, a sequence existing downstream thereof is not read. Accordingly, the self-replication of the self-replicating vector 31 is stopped.
  • a self-replicating vector 41 which is a plasmid vector, includes a reporter gene expression unit 2, a replication initiator protein unit 42 linked thereto, and a replication initiation sequence 3 linked thereto.
  • the reporter gene expression unit 2 includes a target nucleic acid sequence 4, a reporter gene 5 operably linked downstream thereof, and a transcription termination signal sequence 6 operably linked downstream thereof.
  • the replication initiator protein unit 42 is present on the same nucleic acid as the reporter gene expression unit 2 and is a constitutively expressed promoter 44, a sequence 45 encoding a replication initiator protein operably linked downstream thereof, and a downstream thereof.
  • a transcription termination signal sequence 46 operably linked to the.
  • the replication initiation sequence 3 is linked downstream of the transcription termination signal sequence 46 of the replication initiation protein unit 42.
  • the modified base of the target nucleic acid sequence 4 of the self-replicating vector 41 introduced into the test cell may or may not be modified when the vector 41 is introduced.
  • sequences having a promoter activity depending on the degree of modification of the base to be modified of the target nucleic acid sequence 4 are as described above.
  • Such a self-replicating vector 41 behaves as follows after being introduced into a test cell.
  • the replication product generated by the self-replication of the self-replicating vector 41 has the same sequence as the self-replicating vector 41 with respect to the sequence.
  • the modification state of the modified base of the target nucleic acid sequence 4 of the self-replicating vector reflects the modification state of the target nucleic acid present in the test cell.
  • the target nucleic acid sequence 4 is not activated when the base to be modified of the target nucleic acid sequence 4 is modified and the target nucleic acid present in the test cell is highly modified. Therefore, reporter gene 5 is not expressed.
  • the procedure is as follows.
  • the modification state of the modified base of the target nucleic acid sequence 4 of the self-replicating vector 41 reflects the modification state of the target nucleic acid present in the test cell. As a result, the degree of modification at the base to be modified of the target nucleic acid sequence 4 is reduced, and the target nucleic acid sequence 4 is activated. Thereby, reporter gene 5 is expressed.
  • the modified base of the target nucleic acid sequence 4 is not modified, the modified base of the target nucleic acid sequence 4 is modified when the modification state of the target nucleic acid present in the test cell is high. Therefore, the target nucleic acid sequence 4 is not activated. Therefore, the reporter gene is not expressed.
  • the target nucleic acid in the test cell has a low modification state or no modification, the target nucleic acid sequence 4 is activated because the initial modification degree is maintained. Thereby, reporter gene 5 is expressed.
  • the transcription of the sequence 45 encoding the replication initiating protein is controlled by a constitutively expressed promoter 44. Since the constitutively expressed promoter 44 is always in an activated state, it is repeatedly activated. Transcription of the sequence 45 encoding the replication initiation protein is stopped by the transcription termination signal sequence 46. The replication initiation protein is repeatedly generated by the activity of the constitutively expressed promoter 44 regardless of the modification state of the sequence having promoter activity depending on the degree of modification of the base in the sequence of the target nucleic acid sequence 4.
  • Examples of the constitutively expressed promoter 44 may be a cytomegalovirus promoter, a rous sarcoma virus promoter, a simian virus early promoter, and a simian virus late promoter.
  • a replication initiating protein unit 42 is linked downstream of the reporter gene expression unit 2.
  • the replication start sequence 3 is connected downstream thereof.
  • the configuration of the self-replicating vector 41 is not limited to the embodiment shown in FIG.
  • the replication initiation sequence 3 may be linked downstream of the reporter gene expression unit 2, and further the replication initiation protein unit 42 may be linked downstream thereof.
  • the reporter gene expression unit 2 may be linked downstream of the replication initiator protein unit 42, and further, the replication initiator sequence 3 may be linked downstream thereof.
  • the replication initiation sequence 3 may be linked downstream of the replication initiation protein unit 42, and the reporter gene expression unit 2 may be further linked downstream thereof.
  • the directions of the reporter gene expression unit 2 and the replication initiation protein unit 42 are not limited to the embodiment shown in FIG.
  • the direction in which the sequence is read is indicated by an arrow (FIG. 4B).
  • the reporter gene expression unit 2 is read from the left side toward the right side.
  • the replication initiating protein expression unit 42 is also read from the left side toward the right side.
  • FIG. 4C shows an example in which the reporter gene expression unit 2 and the replication initiation protein unit 42 are designed and configured so as to be opposite to each other. In the case of the example of FIG. 4C, the reporter gene expression unit 2 is read from the left side toward the right side.
  • the replication initiating protein expression unit 42 is read from the right side toward the left side.
  • the directions of the reporter gene expression unit 2 and the replication initiation protein unit 42 are not limited to these.
  • the replication initiation protein unit 42 may be arranged, for example, upstream or downstream of the reporter gene expression unit 2.
  • the replication initiating protein unit 42 may be linked so that the replication protein gene is transcribed in the direction opposite to the direction in which the reporter gene is transcribed.
  • the replication initiator protein unit 42 may be linked so that the replication protein gene is transcribed in the same direction as the direction in which the reporter gene is transcribed.
  • FIG. 5A shows a self-replicating vector 51 introduced into the test cell 50.
  • the self-replicating vector 51 includes a reporter gene expression unit 2 and a replication initiation sequence 3.
  • the reporter gene expression unit 2 includes a target nucleic acid sequence 4, a reporter gene 5 operably linked downstream thereof, and a transcription termination signal sequence 6 operably linked downstream thereof.
  • a replication initiating protein unit 52 exists independently of the self-replicating vector 51.
  • the replication initiator protein unit 52 includes a constitutively expressed promoter 53, a sequence 54 encoding a replication initiator protein operably linked downstream thereof, and a transcription termination signal sequence 55 operably linked downstream thereof. Is provided.
  • FIG. 5 (b) shows an example in which the replication initiating protein unit 52 is present on a further vector.
  • the self-replicating vector 51 and the vector 56 including the replication initiating protein unit 52 are both introduced into one test cell 50 as the first vector 51 and the second vector 56, respectively.
  • These introduction methods may be biochemical methods and physicochemical methods as described above.
  • the sequence 54 encoding the replication initiator protein is expressed and transcribed and translated to produce the replication initiator protein.
  • the replication initiator protein recognizes and binds to the replication initiator sequence 3. Further, a plurality of proteins related to DNA replication contained in the test cell are bound.
  • the self-replicating vector 51 is replicated in the test cell by the plurality of bound proteins.
  • the second vector 56 may be referred to as a replication initiation protein gene expression vector.
  • This vector may contain a replication initiator protein unit for expressing the replication initiator protein.
  • the replication initiator protein gene expression vector may be any vector that can express the replication initiator protein in a cell into which the self-replicating vector is to be introduced.
  • Such a vector may be a vector known per se, such as a plasmid vector or a viral vector, or may be a vector having a function of self-replicating itself.
  • the introduction of the self-replicating vector and the replication initiating protein gene expression vector into the test cell may be simultaneous.
  • the replication initiation protein gene expression vector may be introduced into a test cell.
  • a self-replicating vector may be introduced into the test cell prior to the introduction of the replication initiation protein gene expression vector.
  • the self-replicating vector and the replication initiating protein gene expression vector in combination, effective expression of the reporter protein can be achieved, for example, even when the promoter activity is low or the test cell is a low proliferative cell. And enables effective self-replication of self-replicating vectors.
  • a reporter gene expression unit is included in one self-replicating vector.
  • the number of reporter gene expression units contained in one self-replicating vector is not limited to one.
  • the self-replicating vector may comprise at least one reporter gene expression unit and a replication initiator sequence.
  • an example including a plurality of reporter gene expression units as a further embodiment, an example including two reporter gene expression units is shown.
  • the self-replicating vector 61 includes a reporter gene expression unit 2 that is a first reporter gene expression unit, a reporter gene expression unit 62 that is a second reporter gene expression unit, and a replication initiation sequence 3.
  • Replication initiation sequence 3 is present on the same nucleic acid as reporter gene expression units 2 and 62.
  • the reporter gene expression unit 62 includes a target nucleic acid sequence 64, a reporter gene 65 encoding a reporter protein, and a transcription termination signal sequence 66.
  • the target nucleic acid sequences 4 and 64 may be the same nucleic acid sequence or may have different sequences.
  • the reporter genes 5 and 65 contained in the reporter gene expression unit may be the same reporter gene or may be different reporter genes.
  • the transcription termination signal sequences 6 and 66 may be the same sequence or different sequences.
  • a reporter gene expression unit 62 is linked downstream of the reporter gene expression unit 2.
  • the replication start sequence 3 is connected downstream thereof.
  • the configuration of the self-replicating vector 61 is not limited to the embodiment shown in FIG.
  • the replication initiation sequence 3 may be linked downstream of the reporter gene expression unit 2, and further the reporter gene expression unit 62 may be linked downstream thereof.
  • the reporter gene expression unit 2 may be connected downstream of the reporter gene expression unit 62, and further, the replication initiation sequence 3 may be connected downstream thereof.
  • the replication initiation sequence 3 may be linked downstream of the reporter gene expression unit 62, and the reporter gene expression unit 2 may be further linked downstream thereof.
  • the orientation of the reporter gene expression unit and the replication initiation sequence is not limited to the embodiment shown in FIG.
  • the reporter gene expression unit 2 and the reporter gene expression unit 62 are transcribed in the opposite directions, that is, in the opposite direction to the direction in which the reporter gene is transcribed in the reporter gene expression unit 2. May be connected as described.
  • the reporter gene of the reporter gene expression unit 62 may be transcribed in the same direction as the reporter gene is transcribed in the reporter gene expression unit 2.
  • the direction in which the replication initiation sequence 3 is transcribed may be the same direction as the reporter gene expression unit 2 and / or the reporter gene expression unit 62, or may be a reverse method.
  • the expression of the reporter gene expression unit 2, the reporter gene expression unit 62, and the replication initiation protein unit 52 used at the same time in FIG. 6 may all be controlled by one promoter. Alternatively, their expression may be controlled by three independent promoters. Alternatively, two of these three configurations may be controlled by one promoter and the remaining one may be controlled by an independent additional promoter.
  • a preferred example is as follows.
  • the self-replicating vector 61 is designed so that the target nucleic acid sequences 4 and 64 contain the same sequence. At this time, the states of the functional groups in the target nucleic acid sequences 4 and 64 are different from each other.
  • the reporter gene expression unit 2 the target nucleic acid sequence 4 in which the nucleic acid functional group is not substituted is arranged, and in the reporter gene expression unit 62, the target nucleic acid sequence 64 in which the nucleic acid functional group is substituted is arranged.
  • the reporter gene expression units 2 and 62 are designed to have reporter genes encoding different reporter proteins.
  • the difference between the reporter gene expression units 2 and 62 is the presence or absence or degree of substitution by the functional group of the nucleic acid contained in the target nucleic acid sequence 4 and the type of reporter gene. That is, in the self-replicating vector 61, the functional group of the nucleic acid contained in the target nucleic acid sequence 4 is not substituted, but the functional group of the nucleic acid contained in the target nucleic acid sequence 64 is substituted beforehand.
  • a self-replicating vector it is possible to obtain two different types of detection signals from the reporter gene expression units 2 and 62, respectively. With such a configuration, it is possible to distinguish between false positive and false negative signals. Thereby, the assay can be performed with higher accuracy.
  • each element included in the reporter gene expression unit 62 For the details of each element included in the reporter gene expression unit 62, the description of each element included in the above-described reporter gene expression unit 2 may be diverted.
  • Such a second reporter gene expression unit may be included in the first to fourth embodiments.
  • FIG. 7 shows an example in which the replication initiator protein gene expression vector described in the fourth embodiment is used together with the fifth embodiment. These details are as described in the fourth embodiment and the fifth embodiment.
  • Method for obtaining epigenetic genetic information of a test cell As a further embodiment, a method for obtaining epigenetic genetic information of a cell is provided. A method for obtaining epigenetic genetic information of a test cell will be described with reference to FIG.
  • the method of FIG. 8 uses a reporter nucleic acid construct capable of self-replication.
  • this reporter nucleic acid construct copies the state of modification in a specific sequence on the cell's genome during its self-replication in the nucleus of the test cell to its own sequence by functional group substitution. .
  • a detectable signal is then generated depending on the presence of the functional group copied to the reporter nucleic acid construct.
  • such a reporter nucleic acid construct is introduced into a test cell (S81).
  • the reporter nucleic acid construct is self-replicated (S82).
  • the presence / absence and / or magnitude of a signal generated in the test cell is detected (S83).
  • epigenetic information of the test cell is obtained (S84).
  • epigenetic information of cells can be easily obtained.
  • FIG. 9 shows an example of using a self-replicating vector as a reporter nucleic acid construct.
  • a self-replicating vector is introduced into a test cell, for example, a nucleus (S91).
  • the self-replicating vector is self-replicated by culturing the test cell under conditions where the replication initiating protein is expressed (S92).
  • a reporter protein expressed from the reporter gene is detected (S93). This detection may be the presence and / or expression level of the reporter protein.
  • the “predetermined time” may be, for example, a time required for the test cell to divide.
  • Self-replication of a self-replicating vector occurs when a test cell divides. Therefore, the test cell may divide at least once during a predetermined time. Epigenetic information of the test cell is obtained from the detection result (S94). In this method, the state of the test cell may be determined by further checking with a previously associated table. Such a table may be, for example, a table in which cell states or disease states are associated with the presence and / or expression level of a reporter protein. Or you may judge what kind of epigenetic information the epigenetic information of a test cell is concretely from the obtained detection result. Such a method may be performed either in vitro or in vivo.
  • a replication initiation protein gene expression vector is introduced into the nucleus of a test cell (S101).
  • a self-replicating vector is introduced into the nucleus of the test cell (S102).
  • the test cell is incubated. Thereby, the self-replicating vector is self-replicated (S103).
  • the reporter protein expressed from the reporter gene is detected (S104).
  • Epigenetic information of the test cell is obtained from the detection result (S105).
  • the introduced self-replicating vector is allowed to self-replicate in a subject into which the self-replicating vector has been introduced into the nucleus of the cell by maintaining the conditions under which the replication initiation protein is expressed (S111).
  • the reporter protein produced from the self-replicating vector is detected and / or its expression level is measured for the subject (S112). Based on the result, information on the modification in a specific sequence on the genome in the cell included in the subject is obtained (S113).
  • the reporter protein may be, for example, luciferase, ⁇ -galactosidase, nitric oxide synthase, xanthine oxidase, blue fluorescent protein, green fluorescent protein, red fluorescent protein, and heavy metal binding protein.
  • An appropriate detection and / or measurement method can be selected according to the type of the selected reporter protein.
  • a photoprotein gene a fluorescent protein gene, a chromogenic protein gene, an active oxygen-generating enzyme gene, a heavy metal binding protein gene, or the like can be selected as a reporter gene.
  • the photoprotein gene is a gene encoding an enzyme protein that catalyzes a luminescence reaction.
  • Examples of the photoprotein gene include a luciferase gene. Luciferase, which is a translation product of the luciferase gene, performs a luminescence reaction using luciferin which is a kind of substrate.
  • Fluorescent protein gene is a gene that encodes fluorescent protein.
  • Examples of the fluorescent protein gene include a blue fluorescent protein gene, a green fluorescent protein gene, and a red fluorescent protein gene.
  • the chromogenic protein gene is a gene encoding an enzyme protein that catalyzes a chromogenic reaction.
  • Examples of the chromogenic protein gene include ⁇ -galactosidase gene.
  • ⁇ -galactosidase which is a translation product of ⁇ -galactosidase gene, is 5-bromo-4-chloro-3-indolyl- ⁇ -D-galactopyranoside (X-Gal) or o-nitrophenyl- ⁇ -D-galactopyrano.
  • a color reaction is carried out using a substrate such as SID (ONPG).
  • the photoprotein gene, the fluorescent protein gene, and the translation product of the chromogenic protein gene can be detected by an optical detection device.
  • the reporter gene is a luciferase gene
  • the luminescence intensity of the solution may be measured using a luminometer.
  • the reporter gene is a fluorescent protein gene
  • the test cell may be irradiated with light of a specific wavelength, and the intensity of the fluorescence generated from the fluorescent protein in the test cell may be measured with a fluorometer.
  • the reporter gene is a fluorescent protein gene
  • the extract containing the fluorescent protein extracted from the test cell is irradiated with light of a specific wavelength, and the fluorescence intensity generated from the fluorescent protein in the extract is measured by a fluorescence measuring device. You may measure.
  • the reporter gene is a ⁇ -galactosidase gene
  • the ⁇ -galactosidase protein is extracted, a substrate is added, and then the absorbance of the solution is measured using an absorbance measurement device.
  • the active oxygen generating enzyme gene is a gene encoding an enzyme that generates active oxygen.
  • Examples of the active oxygen generating enzyme gene include a nitric oxide synthase gene and a xanthine oxidase gene.
  • Nitric oxide synthase which is a translation product of the nitric oxide synthase gene
  • xanthine oxidase which is a translation product of the xanthine oxidase gene, generate active oxygen.
  • Active oxygen can be detected with an electron spin resonance apparatus (ESR apparatus) or the like.
  • ESR apparatus electron spin resonance apparatus
  • the amount of active oxygen generated may be measured directly, or may be measured using a specific spin trap agent.
  • spin trap agent When a spin trap agent is used, first, the active oxygen generating enzyme is trapped by the spin trap agent, and then the amount of active oxygen generated from the trapped active oxygen generating enzyme is measured.
  • the heavy metal binding protein gene is a gene encoding a protein that specifically binds to heavy metals.
  • the amount of protein bound to the heavy metal may be determined by a magnetic resonance imaging apparatus, a nuclear medicine diagnostic apparatus, or an X-ray computed tomography apparatus.
  • the amount of heavy metal binding protein generated is, for example, as follows. First, a measurable heavy metal is added in advance to a culture solution of a test cell. Next, after washing the test cells as necessary, a heavy metal binding protein is extracted from the test cells. Next, the extracted heavy metal binding protein is imaged with an image diagnostic apparatus corresponding to the heavy metal added to the culture solution, and the amount of heavy metal binding protein is measured.
  • the heavy metal binding protein may be expressed inside the test cell or may be expressed on the outer surface of the test cell.
  • An example of a heavy metal binding protein gene may be a base sequence encoding a metal compound binding peptide.
  • the metal compound binding protein may be a peptide, oligopeptide, polypeptide and / or protein that specifically binds to a specific metal compound.
  • the sequence encoding a peptide that binds to a metal compound may utilize the base sequence of an antibody gene or single chain antibody gene known to bind to the desired metal compound, and based on such base sequence Design.
  • base sequences for example, modifications and / or alterations such as substitution, deletion and addition of one or several bases within the range that maintains the binding with the metal compound, modifications according to the target to be applied, and You may design by modifying.
  • the gene encoding the single chain antibody peptide can be designed from the amino acid sequence of the antibody that binds the metal compound.
  • a gadolinium compound is preferably used because of its high contrast effect.
  • the gadolinium compound may be a metal compound including, for example, gadolinium, gadolinium ions, gadolinium complexes, salts and derivatives thereof, derivatives containing any of these, or analogs of gadolinium compounds.
  • reporter gene may be a reporter gene that presents a metal compound binding ability outside the cell.
  • a reporter gene may be a base sequence encoding a metal compound-binding peptide that is presented extracellularly. Such a base sequence is, for example, transcribed and translated in a cell to produce a metal compound-binding peptide, and the produced metal compound-binding peptide moves to the cell membrane and presents a metal compound-binding ability outside the cell. What is necessary is just to be comprised. Examples of such reporter genes are disclosed in, for example, Japanese Patent Application Laid-Open No. 2012-200245.
  • such a reporter gene comprises a base sequence encoding a metal compound-binding peptide, a base sequence encoding a signal peptide that transports the metal compound-binding peptide to a cell membrane, and the signal peptide.
  • What is necessary is just to include the base sequence which codes the anchor peptide which fix
  • Method for determining characteristics of test cells It is also possible to determine the characteristics of test cells using a method for obtaining epigenetic genetic information of the test cells.
  • the method for determining the characteristics of a test cell includes determining the characteristics of the test cell based on epigenetic genetic information of the test cell.
  • the characteristics of the test cell may be, for example, drug sensitivity, drug adaptability, and the like.
  • determining the characteristics of the test cell may be determining whether or not the test cell is in a specific situation. Determining whether a test cell is in a particular situation may be performed in vitro or in vivo.
  • a method for determining the characteristics of a cell is a method for determining drug sensitivity for a subject from which the test cell is derived, or a drug to be used after surgery for a subject from which the test cell is derived. Or the method for selecting the kind of immunotherapy agent, or the method for judging whether the prognosis of a patient is favorable may be sufficient. Further, for example, the method for determining the characteristics of cells may be a method for obtaining information for making these determinations.
  • the “specific situation” may be a specific health condition, for example, a condition suffering from a specific disease.
  • Specific diseases may be, for example, cancer, mental illness, lifestyle-related diseases, neurological diseases, autoimmune diseases, and cardiovascular diseases. It may be a method for confirming whether the methylation state of an organ induced to differentiate from stem cells in regenerative medicine is normal.
  • a self-replicating vector 31 having a desired target nucleic acid sequence 4 is prepared (a).
  • the self-replicating vector 31 is introduced into a living test cell 50 having a nucleus 71 (b).
  • the self-replicating vector 31 is maintained in a self-replicating state according to conditions in the test cell 50 (b).
  • the test cells are cultured for an arbitrary period under the culture conditions in which the test cells can divide and proliferate in the presence of the replication initiator protein.
  • the modification state of the target nucleic acid sequence in the nucleus 71 of the test cell 50 is reflected in the modification state of the modified base of the target nucleic acid sequence 4.
  • the self-replicating vector 31 has a low degree of self-replication (c).
  • the self-replicating vector 31 has a high degree of self-replication (d).
  • the amount of reporter protein is measured (e).
  • the test cell 50 is a cell with low methylation strength because the base to be modified in the sequence homologous to the target nucleic acid sequence 4 is not methylated or is not modified. It is determined (f).
  • the test cell 50 is determined to be a cell in which the modified base in the sequence homologous to the target nucleic acid sequence 4 is methylated (f).
  • the modification state is reflected in the modification state of the modified base of the target nucleic acid sequence 4 according to the modification state of the target nucleic acid sequence present in the test cell.
  • the modification state of the target nucleic acid sequence 4 can be determined by detecting or quantifying the reporter protein.
  • a method using the self-replicating vector 61 of FIG. 6 will be described as a further example of a method for determining cell characteristics based on epigenomic genetic information.
  • a self-replicating vector 61 having desired target nucleic acid sequences 4 and 64 is prepared.
  • the self-replicating vector 61 is introduced into the test cell 50.
  • the self-replicating vector 61 is maintained in a self-replicating state according to conditions in the test cell 50.
  • the test cells are cultured for an arbitrary period under the culture conditions in which the test cells can divide and proliferate in the presence of the replication initiator protein.
  • the substitution state of the nucleic acid sequence on the genome of the test cell 50 is reflected in the modification state of the modified bases of the target nucleic acid sequences 4 and 64.
  • the expression level of the reporter protein (reporter gene 5) from the reporter gene expression unit 2 including the non-methylated target nucleic acid sequence 4 gradually increases. descend.
  • the expression level of the reporter protein (reporter gene 65) from the reporter gene expression unit 62 including the methylated target nucleic acid sequence 64 does not change.
  • the amount of reporter protein is measured, and the ratio of the amount of reporter protein from reporter genes 5 and 65 is determined.
  • the test cell 50 is determined that the base to be modified in the sequence homologous to the target nucleic acid sequence 4 or 64 is methylated or modified. Therefore, it is further determined that the cell has a high methylation strength.
  • the modification state of the target nucleic acid sequences 4 and 64 is modified according to the modification state of the target nucleic acid sequence present in the test cell. It is reflected in.
  • the modification state of the target nucleic acid sequence can be determined by detecting or quantifying the reporter protein from the reporter gene 5 and the reporter protein from the reporter gene 65, and then taking the ratio between the two.
  • a method for determining whether the subject from which the cells are derived is likely to suffer from a specific disease or not May be provided. Further, information for performing a final diagnosis may be collected based on the epigenetic genetic information of the cells obtained as described above.
  • Diagnosis Method Based on the epigenetic genetic information of the cells obtained as described above, a specific disease in the subject may be diagnosed. In general, such a diagnosis will ultimately involve the judgment of a specialist such as a physician or veterinarian.
  • the “subject” may be an individual such as mammals including humans, domestic animals, pets, and industrial animals, and may be an organ, organ, tissue, cell group and / or single cell obtained from the subject. There may be.
  • a self-replicating vector is introduced into an individual, organ, organ, tissue, cell group and / or single cell that is a detection target.
  • the reporter protein may be detected or quantified.
  • a determination method may be performed as follows.
  • a self-replicating vector is introduced into an individual, organ, organ, tissue, cell group, or single cell to be detected by a biochemical method or a physicochemical method.
  • luciferase which is a translation product of the luciferase gene, is detected depending on the modification state of the base to be modified.
  • the luminescence intensity of the solution may be measured using a luminometer. That is, according to this detection method, it is possible to specifically detect cells in a specific situation using the translation amount of luciferase as an index.
  • Such a diagnostic method is a less invasive method.
  • the detection of luciferase may be performed at a single time point, at a plurality of time points or continuously, or may be performed over time.
  • the diagnostic method is not limited to utilizing detection of luciferase, and may be performed using a reporter nucleic acid construct that produces other detectable signals.
  • a method for determining whether or not a detection target suffers from a specific disease using an organ, organ, tissue, cell group or single cell collected from an individual will be described below.
  • Such a method is, for example, (1) incorporating a self-replicating vector containing a gene that generates a detectable signal as a reporter gene into a detection target including cells under conditions for expressing a replication initiator protein; (2) culturing the detection target for an arbitrary period under culture conditions in which cells as the detection target or cells included in the detection target can divide and proliferate; (3) detecting the signal generated from the detection target; (4) determining whether or not the detection target suffers from a specific disease based on the detected signal; May be included.
  • such a method is, for example, (1) incorporating a self-replicating vector containing a luciferase gene as a reporter gene into a detection target including cells under conditions for expressing a replication initiator protein; (2) culturing the detection target for an arbitrary period under culture conditions in which cells as the detection target or cells included in the detection target can divide and proliferate; (3) extracting a luciferase protein from the detection target; (4) contacting with luciferin which is a substrate of the luciferase protein, and detecting luminescence with a luminometer; (5) determining whether or not the detection target suffers from a specific disease based on information on the detected luminescence; May be included.
  • the cells may be washed before the extraction of the luciferase protein of (3) above. Such an embodiment makes it possible to detect a luciferase protein that is translated according to the state of the cell.
  • the determination regarding the object based on the detection of luciferase may be performed based on information such as the presence or absence of detection of luciferase, whether the detection value of luciferase is larger or smaller than a preset threshold value, or increase or decrease of the detection value. Based on such information, for example, it may be determined whether or not the detection target suffers from a disease having a specific condition as an index, and how serious the disease is.
  • a determination method as follows may be performed.
  • a self-replicating vector is introduced into an individual, organ, organ, tissue, cell group and / or single cell to be detected by a biochemical method or a physicochemical method. Simultaneously with the introduction and / or before and after the introduction, it is brought into contact with a metal compound that forms a binding pair with the reporter protein presented outside the cell depending on the modification state of the target nucleic acid sequence.
  • the metal compound specifically bound to the reporter protein is detected before and / or simultaneously with the contact of the metal compound. That is, according to this detection method, it is possible to specifically detect cells in a specific situation using the presence of the metal compound as an index.
  • the detection of the metal compound may be performed at a single time point, a plurality of time points and / or continuously, and / or may be performed over time.
  • the detection method of the metal compound may be performed using any method known per se according to the type of metal atom contained in the metal compound.
  • any known chemical, physical, physicochemical and / or biochemical method for the detection of metal atoms utilizing the chemical and / or physical properties of metal atoms. May be used.
  • a metal compound for specifically forming a binding pair with the reporter protein may be selected from types that can be measured by an image diagnostic apparatus such as MRI, PET, SPECT, and CT.
  • an image diagnostic apparatus such as MRI, PET, SPECT, and CT.
  • the self-replicating vector can be used in combination with the diagnostic imaging apparatus.
  • cells can be detected with higher sensitivity and more specificity.
  • a method for determining whether a detection target suffers from a specific disease comprises: (1) Incorporating a self-replicating vector containing a reporter gene that presents the ability to bind to a metal compound outside the cell as a reporter gene with respect to a detection target including cells or cells as a detection target (2) presenting the metal compound-binding peptide outside the cell; (3) contacting the metal compound-binding peptide with a metal capable of forming a binding pair with the metal compound-binding peptide; (4) detecting a metal bound to the metal compound-binding peptide; (5) Based on the result of the detection, determining whether or not the detection target suffers from a specific disease; including.
  • an operation for removing the excess metal which has not been bound for example, washing, rinsing, dilution and / or reflux removal may be performed.
  • a method of determining whether or not the detection target suffers from a specific disease based on the metal detection result is as follows. That is, it may be performed based on information such as the presence / absence of metal detection, whether the metal detection value is larger or smaller than a preset threshold, and the increase / decrease of the detection value. Based on such information, it may be determined whether or not the detection target suffers from a disease having a specific condition as an index, and how serious the disease is.
  • an assay kit includes at least one reporter nucleic acid construct, eg, at least one self-replicating vector according to an embodiment.
  • the assay kit may contain one type of self-replicating vector or a combination of two or more types of self-replicating vectors.
  • the assay kit may further contain a carrier known per se carrying a self-replicating vector and / or a container containing the self-vector replicating vector and a replication initiator protein gene expression vector.
  • the assay kit may contain any reagent necessary for performing a method for obtaining epigenetic information of cells or a method for determining cell characteristics.
  • compositions The reporter nucleic acid construct may also be provided as a composition.
  • a composition comprises, for example, at least one self-replicating vector according to an embodiment.
  • One example of a composition may include one type of self-replicating vector or a combination of two or more types of self-replicating vectors.
  • the composition may also contain, for example, a known carrier carrying a self-replicating vector, a replication initiating protein gene expression vector, an excipient, a stabilizer, and / or other components having a desired effect.
  • the composition may be provided in a container.
  • Apparatus As a further embodiment, there is provided an analysis apparatus for performing the method as described above, for example, a method for obtaining epigenetic information and a method for determining cell characteristics using the method.
  • the analysis device includes a gene introduction unit, a constant temperature unit adjacent to the gene introduction unit, a detection unit adjacent to the gene introduction unit, and an analysis unit electrically connected thereto.
  • a self-replicating vector is introduced into the nucleus of the test cell.
  • the self-replicating vector self-replicates in the nucleus of the test cell.
  • the detection unit the reporter protein generated in the cell is detected.
  • Information obtained by the detection unit is sent to the analysis unit.
  • the analysis unit includes a processor, a display unit, and an input unit. In the analysis unit, information obtained by the detection unit by the processor is subjected to data processing and displayed on the display unit as necessary. That is, the result obtained by the detection unit is sent to the processor of the analysis unit, analyzed, calculated and processed according to a predetermined procedure and displayed on the display unit.
  • the inside of the gene introduction part, the constant temperature part, and the detection part is connected to the inside by a communication window so that processing can be performed continuously. After the test cells are transferred from one part to the next part, the communication window is closed by the shielding plate.
  • the procedure for performing the method of obtaining epigenetic information by the analyzer is as follows.
  • the tester puts a container containing the test cell and the self-replicating vector into the gene introduction part.
  • an instruction for starting the analysis is input from the input unit.
  • the instruction from the input unit is sent to the processor, and in accordance with the instruction from the processor, the gene introduction unit performs processing for enabling introduction of the self-replicating vector into the test cell.
  • the introduction process is terminated, and the test cells accommodated in the container are sent to the thermostat. In the thermostat, the test cells are maintained under a predetermined condition for a predetermined time. Thereby, self-replication of the self-replicating vector is performed.
  • the test cells accommodated in the container are sent from the constant temperature part to the detection part.
  • the detection unit the reporter protein expressed in the test cell is detected.
  • the detected information is sent to the analysis unit and processed by the processor.
  • the information thus obtained is displayed on the display unit.
  • the movement of the container to the gene introduction unit, the constant temperature unit, and the detection unit is performed by moving means such as a belt conveyor, a movable arm, and / or a movable tray. All these operations are performed in response to instructions from the processor according to a preset program under the control of the processor.
  • the gene introduction part has a configuration necessary for gene introduction by the selected method.
  • the thermostat has a configuration necessary for satisfying a condition necessary for self-replication of the self-replicating vector.
  • the detection unit has a configuration necessary for detecting the reporter protein according to the signal to be detected.
  • Such an analyzer is useful for easily obtaining epigenetic information of cells.
  • Example 1 Preparation of plasmid-type self-replicating vector A plasmid-type self-replicating vector containing a methylated target nucleic acid sequence was prepared as outlined in FIG. A GFAP gene promoter sequence was selected as the target nucleic acid sequence. A template nucleic acid was amplified and cleaved with a restriction enzyme to prepare a GFAP gene promoter sequence as a target nucleic acid sequence. The obtained GFAP gene promoter sequence is a nucleic acid sequence containing a modified base and having promoter activity. Cleavage with a restriction enzyme was performed, and then this target nucleic acid sequence was methylated with the methylase SssI.
  • the resulting methylated target nucleic acid sequence was ligated with ligase and incorporated into the pM53-R550K vector.
  • the pM53-R550K vector is a vector comprising a reporter gene, an IRES, a sequence encoding a replication initiation protein, a transcription termination signal sequence, and a replication initiation sequence in this order from upstream to downstream.
  • the obtained vector was used as a plasmid-type self-replicating vector containing a methylated target nucleic acid sequence. Details of each step are described below.
  • the base sequences of the primers used for PCR are SEQ ID NOS: 11 and 12, as follows: Forward primer: 5′-CGACGCGTGTCTGTAAGCTGAAGACCTGGC-3 ′ (SEQ ID NO: 11) Reverse primer: 5′-AAAAGTACTCCTGCCCTGCCTCTGCTGGCTC-3 ′ (SEQ ID NO: 12).
  • GFAP gene promoter sequence shown in SEQ ID NO: 1 was obtained.
  • the target nucleic acid sequence contains a base to be modified and has a promoter activity that depends on the degree of modification.
  • This GFAP gene promoter sequence is the 5 ′ upstream region ( ⁇ 1651 bp to +32 bp) of the mouse GFAP gene.
  • the GFAP gene promoter sequence was cloned into a PGV-B2 (TOYO B-Net) vector.
  • the PGV-B2 (TOYO B-Net) vector was digested with the restriction enzyme SmaI. This was dephosphorylated.
  • SmaI restriction enzyme
  • SmaI restriction enzyme
  • T4 ligase T4 ligase
  • the obtained PGV-B2-GFAPp vector is used as a material for obtaining a GFAP gene promoter sequence in the following steps, and at the same time as a PGV-B2-GFAPp vector in the detection test described below for comparison. used.
  • a methylated PGV-B2-GFAPp vector is also prepared by methylating the GFAP gene promoter sequence contained in the PGV-B2-GFAPp vector by the steps described later. This is also used in the detection test described below for comparison. None of the methylated or unmethylated PGV-B2-GFAPp vectors are self-replicating.
  • the PGV-B2-GFAPp vector was cleaved with restriction enzyme Mlu I and restriction enzyme Xho I. Thereby, a GFAP gene promoter sequence to which a restriction enzyme Mlu I and a restriction enzyme Xho I recognition sequence were added was prepared. This sequence was used in the subsequent step as the target nucleic acid sequence.
  • a purified GFAP gene promoter sequence in which the methylated base was not methylated was prepared as an unmethylated control sequence by the same method as above except that Sss I was not added. .
  • the methylation of the GFAP gene promoter sequence contained in the PGV-B2-GFAPp vector obtained in (1) above was also performed in the same manner as described above. Thereby, a methylated PGV-B2-GFAPp vector was obtained.
  • Vector used in the test As an example, the methylated plasmid-type self-replicating vector pM53-R550K-GFAPp vector obtained by the above method and the unmethylated plasmid-type self-replicating vector pM53-R550K- The GFAPp vector was used. These are self-replicating plasmid vectors.
  • a methylated PGV-B2-GFAPp vector obtained by the above method and an unmethylated PGV-B2-GFAPp vector were used. These are plasmid vectors that cannot self-replicate.
  • the ⁇ -galactosidase expression vector pcDNA4 / V5-His / lacZ vector (Life Technologies) was used as the internal standard vector.
  • a lipofectamine / vector complex In a microtube, 0.45 ⁇ L of cationic lipid (Lipofectamine 2000) suspended in 25 ⁇ L of Opti-MEM and 25 ⁇ L of Opti-MEM containing either vector were mixed. This formed a lipofectamine / vector complex.
  • the amount of each vector contained in 25 ⁇ L of Opti-MEM is as follows. For pM53-R550K-GFAPp or PGV-B2-GFAPp, 0.066 ⁇ g of DNA was contained in 25 ⁇ L of Opti-MEM. For pcDNA4 / V5-His / lacZ, 0.033 ⁇ g of DNA was contained in 25 ⁇ L of Opti-MEM.
  • 5-aza-dC reagent was prepared as follows. A 5-aza-dC dilution was prepared by adding 5-aza-dC in PBS to a concentration of 500 ⁇ M. This 5-aza-dC dilution was added to fresh RPMI 1640 medium to make a solution containing 5 ⁇ M 5-aza-dC. The resulting solution was used as a 5-aza-dC reagent.
  • Demethylation was performed as follows. First, after the culture in (c), the medium in each well was removed. Thereafter, 200 ⁇ L of 5-aza-dC reagent was added. As a control for not performing the demethylation reaction, 200 ⁇ L of RPMI 1640 medium supplemented with PBS was added in place of the 5-aza-dC reagent. This was further subjected to adherent culture for 48 hours at 37 ° C. in a 5% CO 2 atmosphere.
  • the culture medium was removed from the culture plate 48 hours after the addition of 5-aza-dC. Each cell was washed twice with PBS, and then luciferase (reporter protein) was extracted from each cell. Specifically, extraction was performed as follows. A cell lysate (PicaGene Cell lysis buffer LC ⁇ , TOYO B-Net) as an extraction reagent was added, and the suspension of cells and cell lysate was incubated at room temperature for 15 minutes. The suspension was then centrifuged with a centrifuge at 15,000 rpm for 5 minutes. Thereby, cell debris was removed from the suspension. Thereby, a supernatant was obtained.
  • a cell lysate PicaGene Cell lysis buffer LC ⁇ , TOYO B-Net
  • luciferase substrate solution PicaGene LT2.0, TOYO B-Net
  • luciferin solution a luciferase substrate solution as a detection reagent
  • the generated luminescence intensity was measured with a luminometer (Mithras LB940, Berthold).
  • FIG. 16 (a) shows data measured for cells into which the PGV-B2-GFAPp vector was introduced.
  • the signal intensity obtained from a cell into which the PGV-B2-GFAPp vector containing an unmethylated target nucleic acid sequence has been introduced and not subjected to demethylation treatment is shown as 100% at the left end of FIG. 16 (a).
  • the relative signal intensity obtained from a cell into which a PGV-B2-GFAPp vector containing a methylated target nucleic acid sequence has been introduced and which has not undergone demethylation treatment is shown. This relative signal intensity was 3.4%.
  • On the right end the relative signal intensity obtained from a cell into which a PGV-B2-GFAPp vector containing a methylated modified base has been introduced and subjected to demethylation treatment is shown. This relative signal intensity was 2.4%.
  • FIG. 15 (b) shows data measured for cells into which the pM53-R550K-GFAPp vector was introduced.
  • the signal intensity obtained from a cell into which a pM53-R550K-GFAPp vector containing an unmethylated modified base has been introduced and not subjected to demethylation treatment is shown as 100%.
  • the relative signal intensity obtained from a cell into which a pM53-R550K-GFAPp vector containing a methylated modified base has been introduced and not subjected to demethylation treatment is shown.
  • the relative signal intensity was 34.1%.
  • the right end shows the relative signal intensity obtained from a cell that has been subjected to demethylation treatment by introducing the pM53-R550K-GFAPp vector containing a methylated base to be modified.
  • the relative signal intensity was 74.6%.
  • the use of the pM53-R550K-GFAPp vector which is a plasmid-type self-replicating vector, which is an example of the embodiment, enabled the following. That is, it has been clarified that its use makes it possible to detect demethylation at the base to be modified using the signal intensity of the reporter protein as an index. That is, these results indicate that the degree of promoter activation varies depending on the modification state of the modified base contained in the pM53-R550K-GFAPp vector. This difference in the degree of activation could be detected using the signal intensity of the reporter protein as an indicator.
  • the embodiment it is possible to obtain epigenetic information about a specific sequence by using a self-replicating vector having a target nucleic acid sequence that is homologous to the specific sequence of the cell.
  • the pM53-R550K-GFAPp vector which contains a sequence homologous to a specific sequence of the test cell and is a plasmid-type self-replicating vector, replicates itself in the test cell, the following occurs. That is, the state of modification at the modified base in the specific sequence of the test cell is reflected in the state of modification at the modified base in the target nucleic acid sequence on the pM53-R550K-GFAPp vector.
  • Example 3 Comparison of methylation rate of CK19 gene promoter region (target nucleic acid sequence) in genomic DNA and reporter vector Reporter vector (self-replicating vector 51) and replication initiating protein gene expression vector (initiating replication) shown in FIG. A vector having a protein unit 52) was constructed. Incorporate the promoter region of the CK19 gene (-617 to +61 bp, SEQ ID NO: 2) as a target nucleic acid sequence into the reporter vector, and compare the methylation rate of the genomic DNA of the test cell into which the vector is introduced and the target nucleic acid sequence of the reporter vector did.
  • the target nucleic acid sequence obtained by PCR was incorporated upstream of the luciferase gene of the reporter vector having the replication start sequence of simian virus 40 to prepare a reporter vector p19sLo shown in FIG.
  • the replication initiation protein gene was the Simian virus 40 large T antigen gene (SV40LT).
  • the gene was amplified by PCR using PrimeSTAR GLX DNA polymerase (TaKaRa BIO) and then incorporated downstream of the cytomegalovirus early promoter of the gene expression vector.
  • SV40LT replication initiation protein gene expression vector pCMV-LT shown in FIG. 17 was prepared.
  • the base sequence of the primer used for PCR is shown below.
  • Detection of methylation rate of genomic DNA CCGG sequence methylation rate contained in the promoter region ( ⁇ 617 to +61 bp, SEQ ID NO: 2) of CK19 gene of genomic DNA (presence or absence of 5-methylation of second cytosine) was examined as follows. That is, it was examined by a methylation detection method using a methylation-sensitive restriction enzyme HpaII and a methylation-insensitive restriction enzyme MspI.
  • HpaII and MspI are restriction enzymes that recognize a common CCGG sequence.
  • HpaII cannot cleave a CCGG sequence containing methylated cytosine (C m CGG), and MspI cleaves a CCGG sequence regardless of methylated cytosine.
  • the solution containing the genomic DNA and reporter vector prepared in (4) above was cleaved with restriction enzymes HpaII or MspI. Then, it refine
  • FIG. 19a and FIG. 19 (b) These results are shown in FIG. 19a and FIG. 19 (b).
  • all the photographs obtained by the above photographing have black backgrounds and white bands.
  • the intensity of the band was digitized by image analysis software as it was.
  • the photograph obtained by the above photographing is taken into a computer, and the image processing software is used to maintain the band strength and the relativity with other data. In this way, an image in which the black and white color is reversed is shown.
  • the black and white colors were similarly reversed in all the photographs taken in the same manner.
  • lane N is a band of PCR amplification product of restriction enzyme-untreated DNA, and represents the total amount of DNA subjected to PCR.
  • Lane H is a band of a PCR amplification product of HpaII-treated DNA. This represents the amount of DNA in which the second cytosine of CCGG is methylated among DNA subjected to PCR.
  • Lane M is a PCR amplification product of MspI treated DNA and represents the detection background. From the result of FIG. 19a, a band of the PCR amplification product was detected in lane H of CCGG sequences A and B, and the band intensity of B was higher than that of A.
  • the methylation rate is calculated from the signal intensity for the PCR amplification product band, but the methylation rate is similarly calculated from the signal intensity for amplification products obtained by other amplification methods. May be.
  • the calculation method of a methylation rate is not limited to obtaining only by the said formula.
  • methylation rate of non-replicating reporter vector was determined by the method shown in (3) above.
  • the human liver cancer cell line Huh-7 was transfected with the reporter vector pC2sLo or with p19sLo alone. The methylation rate was detected using the DNA solution extracted after 96 hours.
  • the replication initiation sequence and the replication initiation protein must coexist in the same cell. Therefore, when p19sLo is introduced into a cell alone, p19sLo does not replicate in the cell.
  • Fig. 20a shows the result of agarose gel (containing ethidium promide) electrophoresis of the PCR reaction solution. From the result of FIG. 20a, no PCR amplification product was detected in lane H of A and B. Therefore, the methylation rate of the CCGG sequence was 0% for both A and B (FIG. 20b). Also, methylation of A and B did not occur in the non-replicating reporter vector.
  • methylation rate of the replication reporter vector was detected using the DNA extracted 96 hours after co-introducing the reporter vectors p19sLo and pCMV-LT into Huh-7.
  • the replication initiator sequence and the replication initiator protein coexist in the cell, so that p19sLo replicates in the cell.
  • PCR was carried out with the same primers as in (6) above, using a restriction enzyme-treated DNA treated with HpaII or MspI and a restriction enzyme-untreated DNA as templates.
  • FIG. 21 a shows the result of agarose gel (including ethidium promide) electrophoresis of the PCR reaction solution.
  • PCR amplification products were detected in Lanes H of A and B.
  • the percentage of methylation of the CCGG sequence was 0% for A and 16% for B (FIG. 21b).
  • DpnI method detection method of vector replicated in cells
  • methylation detection method using HpaII and MspI
  • Example 4 Comparison of methylation rate of COX2 gene promoter region (target nucleic acid sequence) in genomic DNA and reporter vector
  • Example reporter vector self-replicating vector 51
  • replication initiating protein gene expression vector initiating replication
  • the promoter region (-540 to +115 bp, SEQ ID NO: 3) of the COX2 gene was incorporated as a target nucleic acid sequence into the reporter vector.
  • the methylation rates of the genomic DNA of the test cells into which this vector was introduced and the target nucleic acid sequence of the reporter vector were compared.
  • the target nucleic acid sequence obtained by PCR was incorporated upstream of the luciferase gene of a reporter vector having a simian virus 40 replication initiation sequence. Thereby, the reporter vector pC2sLo shown in FIG. 23 was prepared.
  • Genomic DNA and reporter vector from cells were prepared in the same manner as in Example 3 (4).
  • methylation rate of genomic DNA Following is the methylation rate of CCGG sequence contained in the COX2 gene promoter (-540 to +115 bp, SEQ ID NO: 3) of genomic DNA (the presence or absence of 5-methylation of the second cytosine) I investigated as follows. That is, it was examined by a methylation detection method using a methylation-sensitive restriction enzyme HpaII and a methylation-insensitive restriction enzyme MspI.
  • the solution containing the genomic DNA prepared in (5) and the reporter vector was cleaved with the restriction enzyme HpaII or MspI and then purified with the QIAquick PCR purification kit (Qiagen) to obtain a restriction enzyme-treated DNA.
  • PCR was further performed using the following primers. Thereby, the region containing the CCGG sequence of the COX2 gene promoter region of the genomic DNA was amplified (FIG. 24).
  • the PCR reaction solution was electrophoresed on an agarose gel (containing ethidium promide). Thereafter, the PCR amplification product in the gel was visualized by UV irradiation and a photograph was taken. The result is shown in FIG. 25a. From the result of FIG. 25a, the band of the PCR amplification product was detected in the lane H of the CCGG sequences A and B. The band intensity of A was higher than that of B. The percentages of CCGG sequence methylation of A and B calculated by the same method as in Example 3 (5) were 29% and 7%, respectively (FIG. 25b).
  • methylation rate of non-replicating non-methylated reporter vector is determined by the method shown in (3) above, together with reporter vector pC2sLo, or by itself Huh-7 was transfected. It detected using the DNA solution extracted 96 hours after that.
  • the CCGG sequence methylation rate contained in the promoter region (-540 to +115 bp, SEQ ID NO: 3) of the COX2 gene of the reporter vector pC2sLo was examined by the same method as in (5) above.
  • the DNA prepared in (5) above was cleaved with restriction enzymes HpaII or MspI.
  • Fig. 26a shows the result of agarose gel (including ethidium promide) electrophoresis of the PCR reaction solution. From the result of FIG. 26 a, no PCR amplification product was detected in lane H of A and B. The methylation rate of the CCGG sequence was 0% for both A and B, and no methylation of A and B occurred in the non-replicating reporter vector (FIG. 26b).
  • the reporter vector pC2sLo and the replication initiator protein gene expression vector pCMV-LT were co-introduced into Huh-7. It detected using the DNA solution extracted 96 hours after that. PCR was performed with the same primers as in (7) above, using a restriction enzyme-treated DNA treated with HpaII or MspI and a restriction enzyme-untreated DNA as templates. Thereby, the region containing the CCGG sequence of the COX2 gene promoter region of pC2sLo was amplified.
  • FIG. 27a shows the result of agarose gel (including ethidium promide) electrophoresis of the PCR reaction solution.
  • PCR amplification products were detected in lanes H of A and B.
  • the percentage of CCGG sequence methylation was 14% for A and 24% for B (FIG. 27b).
  • DpnI method method for detecting a vector replicated in a cell
  • HpaII and MspI the methylation rate of the COX2 gene promoter region CCGG sequence of only the reporter vector replicated in the cell can be obtained. It was investigated (Fig. 28a). As a result, PCR amplification products were detected in lanes H of A and B.
  • the percentage of methylation of each CCGG sequence was 57% for A and 23% for B (FIG. 28b).
  • the COX2 gene promoter region of the replicated reporter vector was methylated at approximately the same ratio as the COX2 gene promoter region (target nucleic acid sequence) of the genomic DNA.
  • methylated reporter vector pC2sLo alone was transfected into human hepatoma cell line Huh-7. did. After 96 hours, the DNA solution extracted by the method (5) was used. The DNA was cleaved with restriction enzymes HpaII or MspI. Thereafter, it was purified with QIAquick PCR purification kit (Qiagen) to obtain restriction enzyme-treated DNA. PCR was performed using these DNAs and restriction enzyme-untreated DNA as a template using the following primers.
  • FIG. 29a shows the results of agarose gel (including ethidium promide) electrophoresis of the PCR reaction solution. From the results in FIG. 29a, PCR amplification products were detected in lanes H of A and B. The percentage of methylation of the CCGG sequence was 100% for A and 86% for B (FIG. 29b). The methylation rate of the non-replicating methylated reporter vector did not match the methylation rate of the host cell genomic DNA.
  • reporter vector pC2sLo and replication initiator protein gene expression vector pCMV-LT are co-introduced into Huh-7.
  • the DNA solution extracted after 96 hours was used. Restriction enzyme-treated DNA treated with HpaII or MspI and restriction enzyme-untreated DNA were used as templates.
  • PCR was performed with the same primers as in (6) above. Thereby, the region containing the CCGG sequence of the COX2 gene promoter region of pC2sLo was amplified.
  • FIG. 30a shows the result of agarose gel (including ethidium promide) electrophoresis of the PCR reaction solution.
  • Example 5 Detection of demethylation of target nucleic acid sequence (COX2 gene promoter region) by luciferase assay
  • methylated / unmethylated reporter vector pC2sLo alone or together with replication initiator protein expression vector pCMV-LT The liver cancer cell line Huh-7 was transfected. After 72 hours of culture, reporter activity derived from pC2sLo was measured. The culture solution was removed from the 24-well plate and washed with PBS. Thereafter, 150 ⁇ L of cell lysate (Promega) was added, and the mixture was allowed to stand at ⁇ 80 ° C. for 30 minutes or more to freeze.
  • the vertical axis of the graph in FIG. 32 represents the recovery rate of the emission intensity.
  • the recovery rate of the emission intensity is an index of demethylation.
  • the recovery rate of the luminescence intensity is the ratio of the luminescence intensity obtained from the cell into which the methylated reporter DNA was introduced when the luminescence intensity obtained from the cell into which the unmethylated reporter vector was introduced was taken as 100%.
  • the left end of the graph shows the recovery rate of the luminescence intensity of the non-replicating reporter vector, and the right end shows the recovery rate of the replication reporter vector. From this graph, it was found that the recovery rate of luminescence intensity was higher for the replication reporter vector than for the non-replication reporter vector. Thereby, in the replication reporter vector, it became possible to detect demethylation generated in the target nucleic acid sequence with high sensitivity. From this result, it was clarified that epigenetic information on a specific sequence of a test cell can be obtained by using a reporter vector that replicates in a cell, using reporter activity as an index.
  • Example 6 Self-replicating vector having two types of reporter gene expression units (a unit containing a target nucleic acid sequence substituted with a functional group and a unit containing a target nucleic acid sequence not substituted with a functional group) and a replication initiation sequence
  • Vector A reporter vector (self-replicating vector 61) shown in FIG. 6 as an example of the embodiment was constructed.
  • Reporter vector pNL1.1 (Promega) incorporating shrimp-derived luciferase was cleaved with restriction enzymes KpnI and BamHI. The DNA ends were blunted with T4 DNA polymerase. Thereafter, a DNA fragment consisting of Evil luciferase and SV40 transcription termination sequence was purified.
  • This fragment was ligated with p19sLo cleaved with the restriction enzyme SspI and T4 DNA ligase to construct a self-replicating vector p19sLo-NL.
  • a COX2 gene promoter (SEQ ID NO: 3) obtained by methylating cytosine of CpG was incorporated into this p19sLo-NL.
  • the COX2 gene promoter was amplified by PCR using the human genome as a template. The primer sequences used for PCR are shown below.
  • the PCR amplification product (COX2 gene promoter) was purified. Thereafter, a reaction solution (50 mM NaCl, 10 mM Tris-HCl, 10 mM MgCl 2 , 1 mM DTT, 160 ⁇ M S-adenosylmethionine) consisting of the amplification product and reaction buffer was prepared. Thereto, DNA methylase: SssI CpG Methyltransferase (New England Biolabs) was added and reacted at 37 ° C. overnight. Thereby, cytosine in the CG sequence of the COX2 gene promoter was methylated.
  • This methylated DNA fragment (methylated COX2 gene promoter) was ligated to the self-replicating reporter vector p19sLo-NL treated with restriction enzymes KpnI and XhoI by T4 DNA ligase.
  • self-replication including two types of reporter gene expression units (including a reporter gene expression unit including a methylated COX2 gene promoter and a reporter gene expression unit including an unmethylated CK19 gene promoter) and a replication initiation sequence.
  • a reporter vector p19sLo-mC2sNL was constructed (FIG. 33).
  • Example 7 Reporter gene expression unit, replication initiation gene expression unit, and self-replicating vector having replication initiation sequence (1)
  • Preparation of vector A reporter vector (self-replicating vector 41) shown in FIG. 4 as an example of the embodiment was constructed.
  • the replication initiation protein gene expression unit was cleaved with restriction enzymes BglI and BamHI from pCMV-LT (Example 3 (2)). The DNA ends were blunted with T4 DNA polymerase. Thereafter, the DNA fragment of the replication initiation protein gene expression unit was purified. This DNA fragment was ligated to pC2sLo (Example 4 (1)) cleaved with the restriction enzyme SspI to construct a self-replicating vector pC2sLo-CMVLT (FIG. 35).
  • Genomic DNA and reporter vector were prepared in the same manner as in Example 3 (4).
  • the reporter vector methylation rate was determined by introducing the self-replicating reporter vector pC2sLo-CMVLT into Huh-7 and using the DNA solution extracted 72 hours later, as described in Example 4 ( It investigated by the method similar to 7).
  • the solution prepared in (3) above was cleaved with restriction enzymes HpaII or MspI. Thereafter, it was purified with QIAquick PCR purification kit (Qiagen). Using these DNAs and restriction enzyme-untreated DNA as templates, PCR was performed with the same primers as in Example 4 (7) above.
  • FIG. 24 A region containing the CCGG sequence of the COX2 gene promoter region (-540 to +115 bp, SEQ ID NO: 3) of pC2sL-CMVLT was amplified (FIG. 24).
  • the result of agarose gel (including ethidium promide) electrophoresis of the PCR reaction solution is shown in FIG. 36a. From the results of FIG. 36a, PCR amplification products were detected in lanes H of A and B. The ratio of methylation of the CCGG sequence was 9% for A and 0.5% for B.
  • the methylation rate of A was high as in the COX2 gene promoter region of genomic DNA (Example 4 (6), FIG. 25).

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Apparatus Associated With Microorganisms And Enzymes (AREA)
PCT/JP2014/063214 2013-05-17 2014-05-19 細胞のエピジェネティックな情報を得る方法、細胞の特性を判定する方法、薬剤感受性を判断するまたは薬剤若しくは免疫療法剤の種類を選択する方法、疾患の診断方法、並びに自己複製ベクター、アッセイキットおよび分析装置 Ceased WO2014185549A1 (ja)

Priority Applications (4)

Application Number Priority Date Filing Date Title
CN201480028611.5A CN105308188B (zh) 2013-05-17 2014-05-19 方法、自我复制载体、测定试剂盒及分析装置
EP14797267.3A EP2998408B1 (en) 2013-05-17 2014-05-19 Method for obtaining epigenetic cell information, method for determining cell characteristics, method for assessing drug sensitivity or selecting drug or immunotherapeutic agent variety, disease diagnosis method, self-replicating vector, assay kit, and analysis device
JP2015517155A JP6140277B2 (ja) 2013-05-17 2014-05-19 細胞のエピジェネティックな情報を得る方法、細胞の特性を判定する方法、薬剤感受性を判断するまたは薬剤若しくは免疫療法剤の種類を選択する方法、疾患の診断方法、並びに自己複製ベクター、アッセイキットおよび分析装置
US14/943,766 US20160153057A1 (en) 2013-05-17 2015-11-17 Method of obtaining epigenetic information of cell, method of determining characteristics of cell, method of determining drug sensitivity or selecting type of drug or immunotherapeutic agent, method of diagnosing disease, self-replicating vector, assay kit and analytic device

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2013-105481 2013-05-17
JP2013105481 2013-05-17

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US14/943,766 Continuation US20160153057A1 (en) 2013-05-17 2015-11-17 Method of obtaining epigenetic information of cell, method of determining characteristics of cell, method of determining drug sensitivity or selecting type of drug or immunotherapeutic agent, method of diagnosing disease, self-replicating vector, assay kit and analytic device

Publications (1)

Publication Number Publication Date
WO2014185549A1 true WO2014185549A1 (ja) 2014-11-20

Family

ID=51898518

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2014/063214 Ceased WO2014185549A1 (ja) 2013-05-17 2014-05-19 細胞のエピジェネティックな情報を得る方法、細胞の特性を判定する方法、薬剤感受性を判断するまたは薬剤若しくは免疫療法剤の種類を選択する方法、疾患の診断方法、並びに自己複製ベクター、アッセイキットおよび分析装置

Country Status (5)

Country Link
US (1) US20160153057A1 (enExample)
EP (1) EP2998408B1 (enExample)
JP (2) JP6140277B2 (enExample)
CN (1) CN105308188B (enExample)
WO (1) WO2014185549A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3196308A1 (en) * 2016-01-19 2017-07-26 Toshiba Medical Systems Corporation Reporter vector for evaluating characteristics of subject cell, assay kit, procedure and device

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6140277B2 (ja) * 2013-05-17 2017-05-31 東芝メディカルシステムズ株式会社 細胞のエピジェネティックな情報を得る方法、細胞の特性を判定する方法、薬剤感受性を判断するまたは薬剤若しくは免疫療法剤の種類を選択する方法、疾患の診断方法、並びに自己複製ベクター、アッセイキットおよび分析装置
EP3344766B8 (en) * 2015-09-01 2021-03-17 Dana-Farber Cancer Institute, Inc. Systems and methods for selection of grna targeting strands for cas9 localization

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2009232761A (ja) 2008-03-27 2009-10-15 Sysmex Corp メチル化ｄｎａの解析方法
JP2012060894A (ja) 2010-09-14 2012-03-29 National Institute Of Advanced Industrial Science & Technology 時計遺伝子のｄｎａメチル化による概日リズム制御機構のレポーターアッセイ系
JP2012200245A (ja) 2011-03-28 2012-10-22 Toshiba Corp 細胞外に金属化合物結合能を提示するレポーターベクター
JP2013042721A (ja) 2011-08-25 2013-03-04 Toshiba Corp プラスミド型ベクター、遺伝子プロモーター活性の検出方法、及びアッセイキット

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102286524B (zh) * 2011-08-08 2014-04-23 安徽农业大学 一种植物转化载体及其构建方法和应用
JP6140277B2 (ja) * 2013-05-17 2017-05-31 東芝メディカルシステムズ株式会社 細胞のエピジェネティックな情報を得る方法、細胞の特性を判定する方法、薬剤感受性を判断するまたは薬剤若しくは免疫療法剤の種類を選択する方法、疾患の診断方法、並びに自己複製ベクター、アッセイキットおよび分析装置

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2009232761A (ja) 2008-03-27 2009-10-15 Sysmex Corp メチル化ｄｎａの解析方法
JP2012060894A (ja) 2010-09-14 2012-03-29 National Institute Of Advanced Industrial Science & Technology 時計遺伝子のｄｎａメチル化による概日リズム制御機構のレポーターアッセイ系
JP2012200245A (ja) 2011-03-28 2012-10-22 Toshiba Corp 細胞外に金属化合物結合能を提示するレポーターベクター
JP2013042721A (ja) 2011-08-25 2013-03-04 Toshiba Corp プラスミド型ベクター、遺伝子プロモーター活性の検出方法、及びアッセイキット

Non-Patent Citations (19)

* Cited by examiner, † Cited by third party
Title
BARRETO G. ET AL.: "Gadd45a promotes epigenetic gene activation by repair-mediated DNA demethylation", NATURE, vol. 445, no. 7128, 2007, pages 671 - 675, XP002571281 *
CHEN YL ET AL., BIOCHEM. BIOPHYS. RES. COMMUN, vol. 425, no. 2, 2012, pages 290 - 296
CLARK SJ ET AL., NUCLEIC ACIDS RES., vol. 22, 1994, pages 2990 - 2997
COLLAS P.: "Modulation of plasmid DNA methylation and expression in zebrafish embryos", NUCLEIC ACIDS RES., vol. 26, no. 19, 1998, pages 4454 - 4461, XP055295381 *
ESCHER G.: "Demethylation using the epigenetic modifier, 5-azacytidine, increases the efficiency of transient transfection of macrophages", J. LIPID RES., vol. 46, no. 2, 2005, pages 356 - 365, XP002392684 *
FROMMER M ET AL., PROC. NAT'L ACAD. SCI. USA., vol. 89, 1992, pages 1827 - 1831
GONZALGO ML ET AL., NUCLEIC ACIDS RES., vol. 25, 1997, pages 2529 - 2531
HASSE A. ET AL.: "De novo methylation of transfected CAT gene plasmid constructs in F9 mouse embryonal carcinoma cells", BIOCHIM. BIOPHYS. ACTA, vol. 1131, no. 1, 1992, pages 16 - 22, XP023467595 *
HAYATSU H ET AL., BIOCHEMISTRY, vol. 9, 1970, pages 2858 - 2865
HERMAN JG ET AL., PROC. NAT'L ACAD. SCI. USA., vol. 93, 1996, pages 9821 - 9826
HSIEH C.: "Evidence that protein binding specifies sites of DNA demethylation", MOL. CELL . BIOL., vol. 19, no. 1, 1999, pages 46 - 56, XP055295382 *
MAHON M.: "Vectors bicistronically linking a gene of interest to the SV 40 large T antigen in combination with the SV 40 origin of replication enhance transient protein expression and luciferase reporter activity", BIOTECHNIQUES, vol. 51, no. 2, 2011, pages 119 - 126, XP055295383 *
MAJUMDER S. ET AL.: "Role of DNA methyltransferases in regulation of human ribosomal RNA gene transcription", J. BIOL. CHEM., vol. 281, no. 31, 2006, pages 22062 - 22072, XP055295386 *
See also references of EP2998408A4 *
SHERF B. ET AL.: "Dual-luciferase reporter assay: an advanced co-reporter technology integrating firefly and Renilla luciferase assays", PROMEGA NOTES MAGAZINE, vol. 57, 1996, pages 02, XP002937069 *
TAMURA Y. ET AL.: "Epigenetic aberration of the human REELIN gene in psychiatric disorders", MOL. PSYCHIATRY, vol. 12, no. 6, 2007, pages 593 - 600, XP055295384 *
WARNECKE PM ET AL., METHODS, vol. 27, 2002, pages 101 - 107
WISCHNEWSKI F. ET AL.: "Promoter demethylation and histone acetylation mediate gene expression of MAGE-A1, -A2, -A3, and -A12 in human cancer cells", MOL. CANCER RES., vol. 4, no. 5, 2006, pages 339 - 349, XP055295385 *
YOSHIURA K ET AL., PROC NAT'L ACAD. SCI. USA., vol. 92, 1995, pages 7416 - 7419

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3196308A1 (en) * 2016-01-19 2017-07-26 Toshiba Medical Systems Corporation Reporter vector for evaluating characteristics of subject cell, assay kit, procedure and device

Also Published As

Publication number Publication date
EP2998408A1 (en) 2016-03-23
US20160153057A1 (en) 2016-06-02
JP6140277B2 (ja) 2017-05-31
EP2998408A4 (en) 2017-04-19
EP2998408B1 (en) 2020-01-08
CN105308188A (zh) 2016-02-03
JP2014239679A (ja) 2014-12-25
CN105308188B (zh) 2019-03-08
JPWO2014185549A1 (ja) 2017-02-23

Similar Documents

Publication Publication Date Title
Mayer et al. Transcriptional profiling of HERV-K (HML-2) in amyotrophic lateral sclerosis and potential implications for expression of HML-2 proteins
JP6076581B2 (ja) Ｔｉａｂｓを検出するための組成物及び方法
AU2021268634A1 (en) Compositions, systems, and methods for the generation, identification, and characterization of effector domains for activating and silencing gene expression
KR20060034712A (ko) 결장직장암을 위한 생체지표 패널
JP2022527629A (ja) 合成バイオマーカーのための改良された方法及び組成物
CN105861724B (zh) 一种kras基因超低频突变检测试剂盒
CN113166767A (zh) 用于工程合成顺式调控dna的方法
JP5863338B2 (ja) プラスミド型ベクター、遺伝子プロモーター活性の検出方法、及びアッセイキット
JP2023522964A (ja) 無細胞ｄｎａプロファイリングを使用して組織損傷、移植片対宿主疾患および感染を検出する方法
Gasparini et al. Prognostic determinants in epithelioid sarcoma
JP6140277B2 (ja) 細胞のエピジェネティックな情報を得る方法、細胞の特性を判定する方法、薬剤感受性を判断するまたは薬剤若しくは免疫療法剤の種類を選択する方法、疾患の診断方法、並びに自己複製ベクター、アッセイキットおよび分析装置
Zhuang et al. Proteomic characteristics reveal the signatures and the risks of T1 colorectal cancer metastasis to lymph nodes
JP6723011B2 (ja) 被検細胞の細胞特性を評価するためのレポーターベクター、アッセイキット、方法および装置
CN110564850A (zh) 一种ewsr1-tfeb融合基因及其检测引物和应用
CN111793693A (zh) 一种抑癌基因甲基化联合检测试剂盒及其应用
CN116287277B (zh) 胞苷脱氨酶活性的生物标记物及其应用
Li et al. BiFC and FACS-based CRISPR screening revealed that QKI promotes PABPN1 LLPS in colorectal cancer cells
CN104650214B (zh) 肺动脉高压致病基因acvrl1突变位点及其应用
JP6775911B2 (ja) 細胞特性を判定する方法および装置、並びに疾患の検査方法
US20250207173A1 (en) Reporter cell for assessing ddx3 helicase activity
KR20230020820A (ko) 유방암 진단용 바이오마커 및 이의 용도
Pearson Analyzing the suppressive properties of ZNF132 and ZNF154 in head and neck squamous carcinoma
CN120796475A (zh) 一种检测血液融合基因的方法及其相关应用
WO2024236584A1 (en) Cfdna as biomarker for inflammatory bowel diseases
WO2024071424A1 (ja) 細胞内の応答を引き起こす機能性分子の探索方法

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 201480028611.5

Country of ref document: CN

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 14797267

Country of ref document: EP

Kind code of ref document: A1

ENP Entry into the national phase

Ref document number: 2015517155

Country of ref document: JP

Kind code of ref document: A

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2014797267

Country of ref document: EP